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                Abstract 
 
Objective: To estimate the levels of ADAMTS 13 levels and vWF activity in adults with 
dengue fever at presentation and compare it to disease severity  
Setting and design: This is a prospective observational study conducted in the Departments 
of Medicine, Medical ICU and Accident and Emergency Medicine at Christian Medical 
Hospital, Vellore, India. The study recruited participants who presented to the above 
departments from May 2106 to July 2017 
Participants: Consecutive adult patients with acute febrile illness and thrombocytopenia 
with a platelet count less than 1lac/cu mm were selected. After analysis of inclusion and 
exclusion factors they were recruited to the study. Sample for ADAMTS 13 and vWF:CBA 
was collected on day 1 and patients were followed by till death, discharge or convalescence. 
Results: A total of 62 patients were recruited over the above mentioned time period. The 
median age of participants was 22 years with 40 males and 22 females. A total of 15 patients 
had non-severe dengue with no warning signs, 36 had non-severe dengue with warning signs 
and 11 patients had severe dengue. We clubbed the latter two severity grades into “more 
severe dengue” and the former as “less severe dengue” and analysed the data as dichotomous 
outcomes. ADAMTS 13 levels did not correlate with disease severity according to W.H.O. 
grading or to SOFA scores. However, higher levels of ADAMTS 13 meant lesser transfusion 
requirement. On multivariate analysis SOFA score on Day 1 correlated to dengue severity. 
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Introduction 
 
     Dengue fever is a major health problem in India and the world  with a disease burden 
not matched to healthcare resource allocation, especially in resource poor countries like 
India. Dengue fever is caused by the bite of Aedes mosquito, which has a propensity to 
breed near household areas, and has a daytime biting preponderance.  All 4 serotypes of 
Dengue have been reported from India, and it continues to be an ever-increasing healthcare 
problem. In the absence of a proper vaccine, the population at risk in India is large.  
 Clinical manifestations of Dengue are varied and can range from asymptomatic 
illness to a serious life threatening Multi organ dysfunction syndrome (MODS). The WHO 
in 2009 laid down concrete guidelines for Dengue fever classification and management. 
However, the basic pathogenesis of the hematological manifestations and organ dysfunction 
in Dengue fever, that accompanies the severe type remains to be elucidated.  
ADAMTS 13 (A disintegrin like metalloproteinase and thrombospondin like activity 
motif 13) is a serine protease circulating in plasma, and produced mostly by the liver and 
also from the endothelial cells. One of the main functions of ADAMTS 13 is to cleave ultra 
large polymers of vWF (ULvWF) in circulation to small monomers, by binding to the A2 
site of vWF, and regulating the activity of the latter. ADAMTS 13 deficiency is implicated 
in conditions like Thrombotic thrombocytopenic purpura, decompensated liver cirrhosis, 
and anecdotally in a handful of other conditions. It has been hypothesized that alteration of 
relative levels of ULvWF and ADAMTS 13 levels leads to platelet sequestration in  
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circulation, micro thrombi formation and organ dysfunction. Our study aims at proving that 
severe Dengue infections are associated with increased ADAMTS 13 depletion with a 
subsequent increased vWF activity secondary to increased levels of ULvWF.  
Pregnancy is also known to be associated with an altered milieu of coagulation 
factors and relatively low levels of ADAMTS 13. Data on pregnancy outcomes after dengue 
infection is contradictory. However the overt severity of dengue infection in pregnancy 
maybe attributed to the already depleted ADMAMTS 13 levels in pregnancy. However, no 
studies have compared the levels of ADAMT S13 in dengue infected pregnant individuals 
to non- pregnant individuals. The present study also aims to do so.  
 This study thus aims to highlight the role of ADAMTS 13 in the pathogenesis of Dengue 
related thrombocytopenia and its association to disease severity. This might in the long run 
help us to formulate models for early assessment of disease severity, management and 
transfusion strategies in the more severe forms of the disease. 
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Aim and objectives 
Aim: 
To estimate the levels of ADAMTS 13 (A disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) levels and vWF activity in adults with dengue 
fever at presentation and compare it to disease severity . 
Objectives: 
1) To assess if the severity of thrombocytopenia at presentation is correlated with 
 ADAMTS-13 level and vWF collagen activity.  
2) To assess if severity of illness is correlated with ADAMTS-13 level and vWF activity.   
3) To determine if low ADAMTS-13 level and vWF activity are associated with 
 increased mortality. 
4) To analyze ADAMTS-13 levels and vWF collagen activity in pregnant individuals 
 with dengue and compare their levels with non-pregnant individuals with dengue. 
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Review of literature 
  Dengue epidemiology: 
Dengue is a common arboviral infection in the Indian subcontinent and most of 
South East Asia. It is caused by the bite of either Aedes aegypti or Aedes albopticus 
mosquito. The virus belongs to the family Flaviviridae, as does the causative agents of 
Chikunguniya, Japanese encephalitis and Yellow fever to name a few. Four serotypes of 
Dengue virus (DEN1-4) have been described till date, all of which are widely present in 
India. The earliest description of dengue goes back to the latter part of the 18th century when 
it was described as “backbone fever” (1). The term “ Dengue” was coined in 1828 and 
thereafter many epidemics from different parts of the world have been reported.   
The earliest report of Dengue fever in India dates back to 1946 (2). The first isolation 
of dengue virus in India was in 1956, shortly after the isolation of the same in Japan in 1944 
(1). Subsequent reports had shown the presence of isolated serotypes of dengue virus. In the 
1968 epidemic of Dengue, all four serotypes were described (3). This fuelled further 
epidemiological studies of dengue in India and helped draw the serotypes involved in 
subsequent epidemics. Over the years there has been significant variation in the prevalence 
of particular serotypes, patient demographics and the outcomes.  
The menace of this arboviral illness is not limited to the tropical climates or the third 
world countries. The estimated global burden of Dengue is huge and WHO estimates 
around 50 million dengue infections every year with more than around 1% of them having  
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signs of disease severity requiring hospitalisation (4). The highest burden of the severe 
forms of disease are however in the Sub-Saharan Africa and South East Asia. Other than 
South East Asia, the South American countries are also seeing growing incidence of 
Dengue fever(5). In the 2017 biweekly report by WHO, an early increased incidence of 
disease was noted in Philippines and Vietnam, which seemed to be dying down by May 
2017(6). Over the years there seem to be growing disease incidence, however this can also 
be because of more awareness and better reporting, than the actual increase in disease 
occurrence.  In India, there exists significant discrepancy between actual disease incidence 
and reporting. Despite that, data from National vector borne disease control program has 
shown progressive increase in both the number of cases and deaths throughout the country 
over the last 10 years (7).  The data quite obviously highlights that states, which have better 
healthcare framework and networking, have more reported dengue cases and death. This 
undermines the bulk of disease burden through reporting bias. Case definition of dengue has 
been standardized which leads to earlier diagnosis and confirmation with more readily 
available laboratory resources.  This helps in better diagnosis at the primary care level, 
which ideally should translate into better practices and more favorable outcomes.  
The epidemiology of dengue is evolving throughout the world and India. A close 
monitoring and pattern recognition of new cases in the community might help us in 
preventing major epidemics. As of now dengue remains a preventable burden for a vast 
majority of people in our country.  
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Dengue virus and pathogenesis: 
Dengue virus belongs to the family Flaviviridae and genus Flavivirus. It was first 
isolated in Japan in 1944 (8). In India the virus, DEN 1 serotype, was first isolated in 1956 
at Christian Medical College, Vellore (1). It exists in 4 serotypes that provide serotype 
specific lifelong immunity. There is significant genetic and molecular heterogeneity 
amongst the serotypes, with only around 65% of shared characteristics at the amino acid 
level (4,9,10). Within each serotype there are several genotypes that differ at the genetic 
level by about 3% (9). Structurally the virus has an icosahedral nucleocapsid, which 
encloses a single stranded RNA genome with the mature virions being around 50 nm in 
diameter (11). The virus contains three structural proteins and seven non-structural 
(designated as NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins, which is covered 
by the lipid envelope. The structural proteins namely, the capsid, pre-membrane/membrane 
(prM/M) and the envelope protein which provides the icosahedral symmetry(9). The 
structural proteins are primarily involved in cellular attachment and infection. Cryoelectron 
microscopy showed the virus to be smooth on the exterior and also elucidates the role of 
many of the structural proteins in viral pathogenesis. 
The environment and transmission:  Dengue infection more commonly results in 
inapparent infection, accounting for over 75% of infected cases, with an estimated around 3 
million apparent infections in 2010 (9,12). The huge number of inapparent infections forms 
the most common natural reservoir of the disease in Nature. Disease transmission depends 
on host, environment and host factors as with most arboviral illnesses. The more important 
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factors pertaining to the host include their age, prior dengue infection, temporal difference 
from prior dengue infection and their immunological memory, presence of other 
comorbidities etc. (10). Overcrowding and presence of vector breeding grounds close to 
habitat have consistently shown to promote disease transmission (13). Breakthrough 
epidemics are often due to viral genomic assortment producing strains with more replicative 
capabilities in both humans and the vectors (14).  Studies have shown that newer virulent 
strains often replace lesser virulent and replicative strains providing a survival advantage to 
the virus. Together with waning of population immunity might explain resurgences of 
dengue at an epidemic scale. This has been postulated to be one of the reasons for increased 
epidemicity of South Asian dengue compared to South America (14).   
The Aedes mosquito dwells near human habitat. Female Aedes are the commoner 
vectors and become viremic after having a blood meal from a viremic human. Vertical 
transmission in mosquitoes has been reported, however it is not the common mechanism of 
viral transmission. Environmental factors like increased humidity, as is experienced in the 
monsoon and in the months following that is a strong factor in vector propagation (13). 
Increased diurnal variation of temperature lead to increased vector survival and 
dissemination of infection. The effects of this vary between the species of Aedes mosquito, 
but on the whole, positively affects disease propagation (15). Different models have been 
implicated in the interplay between environmental factors, vector, host and the virus that 
leads to Dengue infection. The following diagram (Fig. 1) depicts that these interplay are 
intricate and decide both vector propagation and disease transmission in the community that 
ultimately defines the disease incidence (16) . 
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Fig. 1. Interplay of environment, vector and host factors in dengue transmission 
Thus dengue infection depends on multiple factors. At each step there can be efforts to abort 
the passage of the virus downstream ultimately halting human infection. 
Viral entry and infection:  Transmission of the virus via the vector to a susceptible 
individual leads to inoculation, which in proper circumstances leads to Dengue infection. 
This phase starts from the blood meal of the Aedes mosquito during which the virus is 
inoculated into the bloodstream of the human host, subsequent viral replication and 
maturation followed by transmission during a subsequent mosquito bite of the newly formed 
virions to another host.   
Post inoculation into the host blood, the dengue virus binds to specific cell surface 
receptors like mannose receptors, glycosaminoglycans and certain members of the C type 
lectin family. The primary cell types that are targeted include the dendritic cells, hepatocytes, 
platelets, endothelial cells, though it can virtually infect any cell of the body. The dengue 
virus has a lipid bilayer membrane containing the M and E proteins, which are involved 
	 16	
  
primarily in the initial viral-host interaction (17,18). Once the virus has attached itself to the 
cellular membrane proteins it is internalized via clathrin mediated endocytosis (9,19) . Once 
viral entry inside the cell is successful there is fusion of the viral and endosomal membranes 
and the downstream cascade for generation of viral progeny is set forth.  
Viral protein synthesis: The initially formed negative sense viral RNA drives the 
formation of the positive strand RNA. Multiple organelles of the infected cell are involved in 
this function, including but not restricted to the Endoplasmic reticulum, Golgi apparatus and 
the cell membrane. The entire genome is around 10 kb comprising of a positive sense RNA 
that codes for a total of 10 proteins (3 structural and 7 non-structural, designated as ‘NS’) The 
positive strand viral RNA once formed is translated with the help of the host cellular 
machinery into a single poly-protein. This undergoes post-translational modification and is 
spliced into the 3 structural and 7 non-structural proteins, which have been mentioned before.  
The following diagram adapted from Aruna et al, schematically depicts dengue virus, entry, 
replication and association (19).  
The newly formed RNA is assembled into progeny virions, which bud into enveloped 
immature virions. The newly budding virus can be either mature or immature. The former are 
infective and contains the processed M protein on the viral surface while the latter immature 
forms contain the uncleaved form of the protein denoted as ‘prM’(9,17,19). Biochemical 
changes at the time of virus budding renders the immature virions into mature infective 
particles. 
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       Fig. 2: The infection and replication of dengue virus 
 
The differential confirmation of the E and M proteins provide the virions with the 
ability to infect different cell types and is a dynamic process (10). The structural proteins 
participate in viral entry and establishing infection while the NS proteins are involved 
directly in viral replication and packaging of new virions. The NS1 protein is transported 
subsequently to the cellular membrane and in the soluble, lipid-associated form is detectable 
in blood from the very early stages of infection (17). It thus plays an important role in early 
diagnosis of dengue infection in the community. NS1 has also shown to play an important 
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 role in complement activation, while some of the other NS proteins have a direct association 
with the viral RNA polymerase, possibly as cofactors. 
Immunopathogenesis:  The pathogenetic landscape of Dengue virus is varied and 
includes evading both the innate and active immunity, while having a myriad of direct 
cytopathic effects.  As the infection is set into motion and the virus uses the host cellular 
machinery to proliferate, the immune system and the virus plays a hand in hand role leading 
to organ damage.  
At the onset the virus bypasses the innate immune system by directly infecting the 
cells of the innate immune system. These cells, which primarily include the epidermal 
macrophages (Langerhans cells), keratinocytes and blood monocytes carry the dengue virus 
to the local lymph nodes. Here more cells of the mononuclear macrophage cells are recruited 
resulting in viral amplification and propagation of the infection (20).  The occurrence of prior 
infection with dengue determines serotype specific immunity and modulates the immune 
response. The final outfall depends on the adaptability of the immune response to the current 
infection and the virulence of the organism. The following factors have been shown to play 
primary roles in dengue pathogenesis: 
a) Host factors: 
Host immunity:  The immune background plays the most determining role in dengue 
infection and extent of disease. The involved components of the innate immune system in this 
include the Toll like receptors (TLRs) and other intracellular sensors (Retinoic acid inducible 
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 gene 1, Melanoma differentiation associated gene 5) that translate to increased production of 
IFN gamma, the main defense against dengue virus proliferation (21).  The initial recognition 
of Pathogen associated molecular patterns (PAMPs) in the form of viral nucleic acids by the 
monocyte-macrophage cell lines form the initial defense to infection. The virus has multiple 
evasion techniques from the above surveillance, including proteases (NS2B/3) that down 
regulates the interferon response, to altering protein structure abetting cellular stress signals. 
In a study on 97 children with Dengue infection, Singla et al showed that while the severity 
of dengue infection did not correlate with the viral load, lower interferon responses did (22). 
The virus is astute at bypassing multiple innate immunological checkpoints and progresses 
through the infection, while at the same time offsetting the adaptive immune response into a 
flaw.  
  Post infection with any viral serotype, homotypic immunity is generated that last for 
a significant duration, while a short-lived immunity is generated against the other serotypes. 
The specificity of this protection evolves after a short time post infection, however it gives 
for over an year some amount of protection against severe diseases by other serotypes (17).  
The antibodies are directed against the viral structural proteins and whilst they are important 
for homotypic immunity, they drive the pathology in heterotypic infection (23). Most of these 
antibodies in circulation are non-neutralizing and accelerate viral entry into cells as well as 
impede interferon production in the absence of blocking neutralizing antibodies (24,25).  This 
mechanism known as Antibody Dependent Enhancement  (has been implicated behind the 
more severe forms of Dengue like Dengue Hemorrhagic fever (DHF) and Dengue shock 
syndrome (DSS) (21). This underlies the biology behind increased severity of delayed 
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 heterotypic infection. Figure 3, adapted from Whitehead et al schematically depicts the 
mechanism of ADE. The ability of non neutralizing antibodies in aiding the virus to infect 
cells expressing the IgG FCγ receptors have been widely studied and have shown to increase 
viral infectivity, output and immune dysregulation (26). ADE leads to increased viral load 
while also up regulating pathways that culminate into more tissue damage and disease 
severity.  
  
Fig. 3: Heterotypic antibody mediated enhancement of viral transformation and disease severity 
Other mechanisms that have been implicated include direct complement activation, 
transient autoantibody generation to antigens like plasminogen, and deregulated auto-reactive 
T cell response, though these do not appear to be the primary pathologies (10,20). Thus host 
immunity plays an important role in pathogenesis of dengue infection and is strongly guided 
by any prior dengue/Flavivirus infection.  
Host demography and genetics: The role of genetics in modulating dengue infection is less 
well known. Certain HLA types have shown increased preponderance to more severe disease 
(17,27). DC-SIGN a C-type lectin is used by all dengue serotypes to infect dendritic cells 
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 (28). Polymorphisms of the same have been shown to predict increased dengue severity in 
one study in India. Given the homogeneity of its role across all dengue serotype infections, 
antibodies against it is being studied as a novel target for dengue vaccines (29).  Age is a 
definite risk factor in dengue severity with both the children and elderly doing poorly. 
Children have increased vascular permeability following dengue infection leading to 
increased prevalence of DHF and DSS.  In the elderly the presence of other comorbidities and 
poor organ reserves leads to early de-compensation and increased disease. 
Pregnancy and dengue: Pregnancy is an added risk factor in dengue severity. The biological 
plausibility lies in pregnancy being a state of increased blood volume with decreased hemo-
concentration and alteration in the milieu of coagulation factors and increased capillary 
permeability. Machado et al in a retrospective study from Rio de Janerio, Brazil compared 
severity of Dengue infections between pregnant and non-pregnant individuals (30). Amongst 
a total of 151064 cases of dengue infection over 2 years (Jan 2007-Dec 2008), they had 561 
female patients in the age group 15-49 years (considered reproductive age group in this 
study) of which 99 patients were pregnant. Multivariate analysis showed pregnancy to be a 
risk factor for dengue severity with an Odds ratio of 3.38 (95% CI: 2.1-5.42). Tan et al in a 
prospective study from Malaysia showed that pregnant women who presented with 
miscarriage (upto 22 weeks) tested more commonly positive for dengue (Dengue specific 
IgM or NS1Ag) when compared to controls by an adjusted OR of 4.2 (95% CI 1.2-14), 
though the absolute difference was not large (31). In a retrospective cohort from Western 
French Guana, Friedman et al, showed that incidence of pre-term birth and low birth weight 
infants were modestly increased in mothers who had dengue infection during pregnancy (32). 
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 A prospective study from South India looking at 73 pregnant women with Dengue fever over 
an 18 month period showed 4% of them to have fetal loss, 22% premature delivery with 
dengue in very early or late gestation having a poorer feto-maternal outcome (33).  Pregnancy 
thus poses a heightened risk and early diagnosis with adequate management is important for 
both the mother and the fetus. 
b) Viral factors: 
 The role of different viral serotypes and further subtypes of the same serotype 
attributing to disease severity has been widely studied. The virulence of these different 
serotypes range from their ability to infect mosquitoes establish human infection, infect 
human dendritic cells to modulating the immune response and direct cytopathic effect. 
Cologna et al developed laboratory dengue models and showed the DENV 2 South Asian 
genotype had increased ability to infect Aedes aegypti mosquito, human dendritic cells and 
viral output compared to the American genotype (14). Certain studies have shown the order 
of infections by different serotypes to be important while others have shown the time gap 
between primary and secondary infection to play an important role in disease severity.  The 
role of the viral factors in disease severity is seldom in isolation and includes interplay 
between host immunity, demographics, and environment with the former. However the 
penetrance of a new viral serotype in a population naïve to it assumes significance and is 
probably the most important factor determining its virulence.  
Pathogenic landscape: We have mentioned the role of the host, environment and immunity in 
establishing infection. The subsequent pathogenic processes that occur downstream 
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 subsequently lead to organ injury and disease. The pathways involved are many and many 
approaches have been used to elucidate it.  Martina et al in a seminal paper used an 
integrated approach to dengue infection and disease. The initial viral entry is associated with 
immune activation and dysregulation, viral multiplication in cells of the mononuclear and 
reticulo-endothelial system, subsequent cytokine storm leading to increased vascular 
permeability and endothelial cell dysfunction (20). There is direct virus mediated damage to 
hepatic cells, coagulopathy secondary to disruption of the intrinsic plasminogen-plasmin 
system as well as a consumptive thrombocytopenia. The effect of the above pathologies lead 
to the following: 
a) Increased vascular permeability with capillary leak 
b) Hepatotoxicity 
c) Coagulopathy 
d) Thrombocytopenia 
Though the above list is in no way exhaustive, it forms the bedrock of the culminating 
effects of dengue infection in humans. Several mechanism have been described above that 
can explain the above pathologies, however most work in unison and becomes more 
prominent in the more severe forms of the disease. Fig. 4 depict a schematic diagram tries to 
put together the different pathways implicated in the disease process. Organ pathology is 
global and includes the central nervous system, lungs, liver, GI tract, hematopoietic system 
and most importantly the cardiovascular system. The exact mechanism involved is difficult to 
delineate but the final end point lies in diffuse endothelial cell dysfunction coupled with an 
abnormal coagulation response.  
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Dengue induced thrombocytopenia: On the most consistent pathology in dengue infection is 
thrombocytopenia. It is as much an effect of the infection as it is a driver of the severe forms 
of infection, like DHF. Multiple mechanisms working in unison have been described in the 
pathogenesis of thrombocytopenia in dengue. Some of the possible mechanisms are: 
a) Transient bone marrow suppression:  
-  Direct cytotoxicity by the virus on megakaryocytes 
-  Cytokines preventing maturation of megakaryocytes to platelets 
-  Antibodies directed against megakaryocytes 
-  Macrophage activation syndrome 
b) Increased peripheral destruction: Immune mediated; Apoptosis 
c) Consumptive thrombocytopenia 
-  Akin to disseminated micro-thrombi and platelet sequestration as in TMA  
Dengue virus is known to directly infect platelets in circulation as well as their 
precursors in the bone marrow. The virus gains entry into cells via various receptors like the 
TLRs, DC-SIGNs and causes platelet activation (34). Ojha et al showed that dengue virus 
infection of platelets led to platelet activation and a linear relationship between the viral load 
and the level of activation leading to platelet micro particle, clot formation and a form of 
consumptive thrombocytopenia (35). They also showed that virus infected platelets were 
more readily phagocytosed by the monocytes. Thus multiple mechanisms are at play even 
when direct virus related cytotoxicity is considered. Anti platelet antibodies are also present 
in dengue infection and mediate opsonisation followed by complement-mediated lysis. IgM 
antibodies against platelets in dengue have been shown to prevent aggregation and promote 
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 lysis (36). These antibodies have been also shown to be higher in the severe forms of dengue 
fever (DHF/DSS) compare to the non-severe forms.  A lot of these autoantibodies generated 
by molecular mimicry between the dengue virus and coagulation factors function like de-
novo anti-thrombin antibodies and promote fibrinolysis as well as propagate 
thrombocytopenia (37).  
Thrombocytopenia alone is not the only platelet anomaly in dengue as it is usually 
accompanied by platelet dysfunction. Multiple studies have shown decreased platelet 
activation and aggregation in dengue to adequate stimuli, some mechanisms of which have 
been described above (38). Platelets play a vital role in viral propagation and endothelial 
dysfunction as well thereby acting as effectors in dengue pathogenesis as well. While no 
unified concept can be drawn several factors working in consort determine the level of 
platelet dysfunction and the severity of dengue.  
ADAMTS 13 and Dengue:  As new concepts get drawn to understand better the pathogenetic 
mechanisms in dengue, it becomes clearer that the virus has myriad effects and works 
through several pathways, with some more abrogated than the others.  
ADAMTS 13 (A Disintegrin And Metalloproteinase with Thrombospondin type 1 
repeats) is a zinc metalloproteinase that which is primarily produced by the stellate cells of 
the liver and in to a lesser extent by the endothelial cells and platelets (39,40).  It belongs to 
the family of ADAM proteins, that function as zinc serine protease and has been implicated 
in multiple physiological processes like neural cell development and migration, fertilization 
as well as in pathologies like malignancy, asthma and cardiac hypertrophy (41,42). 
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  ADAMTS 13 is secreted as a constitutively active enzyme into the plasma and its 
main function is to cleave ultra-large polymers of von Willebrand factors (ULvWF) into 
smaller lesser potent vWF structures (43). vWF is synthesized and secreted in large 
polymeric forms from the Webel Palade bodies of endothelial cells and platelets and have an 
important role in hemostasis, by acting as a physiological sensor in vessel injury and 
promoting hemostasis by platelet adhesion to the site of injury as well as binding to other 
matrix proteins (44). The thin line between hemostasis and thrombosis entails that the 
function of vWF needs to be regulated. The ULvWF have a higher hemostatic potential 
(often thrombogenic) with it correlating directly to the length and thickness of the polymers 
(45). This delicate balance is maintained by two mechanisms: 
1) The tertiary structure of the vWF protein 
-  This reduces the accessibility of the protein to the intact vasculature and prevents its 
adhesion to the vasculature, platelet activation and thrombus formation in normal state. In 
physiology the vWF is present as a globular fold, which in presence of vessel damage 
undergoes a structural transition secondary to the shear stress, exposing the different binding 
sites (to platelets and vessel wall) and promoting hemostasis (46).  This intricate 
housekeeping mechanism provides the first line of control on the function of vWF. 
2) ADAMTS 13 mediated cleavage of ULvWF: 
-           As mentioned above, ADAMTS 13 cleaves ULvWF polymers into monomers, 
thereby reducing their thrombogenic potential to a more balanced hemostatic one. 
ADAMTS13 binds to the A2 portion of vWF protein, which is properly exposed on unfolding 
of its globular structure. Though ADAMTS 13 can bind to the globular ULvWF, only on 
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 unfolding of the vWF on exposure to shear stress, does the bond strengthen and further sites 
become accessible leading to cleavage of the latter (47). The action of ADAMTS 13 on VWF 
thus occur at the following places (44): 
a) ULVWF in circulation 
b) Newly secreted vWF polymers from platelets and endothelial cells 
c) Unfolded vWF at the site of platelet plug. 
 
The function of ADAMTS 13 in physiology is as important as its role in pathological 
conditions. Congenital deficiency of ADAMTS 13 is associated with Upshaw-Schulman 
syndrome, which presents with a congenital form of thrombotic thrombocytopenic purpura 
(TTP) (48). Acquired deficiency of ADAMTS 13 leads to a the more commoner form of 
TTP, first described as Moschowitz’s disease by Singer et al in 1942 (43). Acquired 
deficiency is seen secondary to the presence of autoantibodies inhibiting ADAMTS 13 
function in majority of the cases, while around 10% is secondary to increased antibody 
mediated clearance of the same (49).  TTP is defined by the presence of thrombocytopenia, 
microangiopathic hemolytic anemia, renal failure and central nervous system disturbances. 
Most studies have showed ADAMTS 13 deficiency in excess of 90% cases of idiopathic TTP 
(43). Severe deficiency of ADAMTS 13 is specific for TTP with values < 5% being shown to 
be discriminatory from other causes of thrombocytopenia (50). Treatment consists of plasma 
or cryosupernatant infusion, plasma exchange, and ADAMTS13 concentrate infusion, 
together with immunomodulation.  
 
	 28	
 
The role of ADAMTS 13 and dengue has recently come to light. As dengue as a 
disease is associated with thrombocytopenia with multiorgan dysfunction secondary to many 
reasons (hypoperfusion, immune dysregulation, micro-thrombi formation), a biological 
plausibility existed between the pathogenesis of ADAMTS 13 deficiency and dengue fever 
though not very apparent. Anecdotal reports exist about TTP in dengue, however in one 
report of a pregnant woman diagnosed with dengue infection related TTP by Kadhiaravan et 
al, ADAMTS 13 activity was normal (51,52). Different viruses (both RNA and DNA) have 
been shown to cause TTP, but most are rare and have a varied presentation, with a very few 
being directly attributed to ADAMTS 13 deficiency (53). Rossi et al reported a 45-year-old 
gentleman with diagnosed dengue fever and developed features of thrombotic 
microangiopathy (TMA) on the 11th day of illness (54). The authors showed the presence of 
anti-ADAMTS 13 IgG antibodies, which correlated with a lower ADAMTS 13 activity. This 
was the first report that looked at ADAMTS 13 pathology in dengue related 
thrombocytopenia and microangiopathy. Djamiatun et al in a cohort of 73 patients from 
Indonesia with dengue  (43= Non severe dengue, 30= DHF and DSS) compared the levels of 
ADAMTS 13, vWF:Ag (as a surrogate marker for vWF activity) amongst other to outcomes 
(55). ADAMTS 13 was done for a selected group of 15 patients from the subgroup of severe 
dengue. They found that high vWF:Ag levels were higher and ADAMTS 13 levels were 
lower in individuals with severe dengue compared with healthy controls, though the levels 
were not compared for with those having non-severe dengue. Though limited by numbers, its 
points towards the clinical relevance of ADAMTS 13 and vWF activity in propagating 
pathogenesis in severe dengue. In another prospective cohort study of 42 children with  
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dengue (20= Non severe dengue, 23= DHF), Sosothikul et al showed that DHF is associated 
with endothelial activation and injury, an aberrant hemostatic system and decreased levels of 
ADAMTS 13 when compared with patients with non severe dengue (56). They also showed 
the presence of abnormal vWF multimers only in those with DHF. These studies throw light 
on lesser-known mechanisms of thrombocytopenia in dengue and a potential new marker that 
can be used to assess severity early into the disease. As such if this is considered a major 
mechanism in pathogenesis of severe dengue, platelet transfusions can prove detrimental, 
because it might promote disseminate micro-thrombi formation and organ dysfunction (57). 
Lee et al did a non randomised retrospective observational study on 788 patients with dengue 
infection in Singapore and compared the outcomes between those who received prophylactic 
platelet transfusion (N= 486) to those who did not (N=302) (58). They showed while 
individuals who received platelet transfusions had a slower platelet increment than the other 
group, there was no difference in the incidence of ICU admission or death between the two 
groups. Large surveys have not shown consistency in indications for platelet transfusion (59). 
As such the guidelines published by the National Vector borne diseases control Programme 
(NVBDCP), India in 2008 laid down guidelines for platelet transfusion, which includes (60): 
- Prophylactically when platelet count is <10,000/cu mm in the absence of any bleeding 
- Major systemic bleeding manifestation, usually together with packed red cells 
- Severe coagulopathy with prolonged shock. 
Recommendations are still lacking about prophylactic plasma infusions in dengue 
patients with thrombocytopenia, however as our knowledge of the pathogenesis of severe 
dengue improves, it might soon dominate transfusion practices.  
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Diagnosis and Management:  The crux of dengue management lies in early clinical 
case recognition, risk stratification and initiation of management. As laboratory facilities 
adept for serological diagnosis of dengue are not widely available in resource poor settings, 
using the conglomerate of clinical signs and symptoms together with basic blood 
investigations are prudent in case identification.  
The WHO case definition of dengue includes an acute febrile illness in the correct 
epidemiological setting, which is then classified based on severity. The WHO guidelines 
from 2009 and initially replaced the prior terminologies of DHF and DSS and introduced the 
classification of dengue fever into severe and non severe forms (61). The rationale was to 
ensure early assessment of clinical severity and initiation of measures to prevent multiorgan 
dysfunction. Fig. 5 adapted from the WHO 2012 guidelines on dengue management shows 
the disease classification according to severity (62). The case classification includes a 
conglomerate of symptoms, clinical examination findings and basic laboratory tests, which 
are expected to be readily and widely available. Moving past the prior classification of 
dengue, this helps in an early assessment of disease and setting treatment goals before the 
onset of severity.  
The clinical presentation of dengue fever is of a continuous spectrum that can extend 
from a short duration flu like illness to a severe condition associated with multi-organ 
dysfunction. Most patients present with an acute febrile illness, accompanied by headache, 
myalgia and fatiguability. Clinical diagnosis is thus the bedrock while laboratory evaluation 
helps assessing the severity of organ dysfunction and confirming the diagnosis.  
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The initial assessment also should consider other differentials, which in our setting 
includes the following, but is not limited to; 
- Other viral hemorrhagic fevers: Chikunguniya, Hantavirus 
- Malaria                - Rickettsial infections: Scrub typhus 
- Leptospirosis            -Viral coryza, Influenza 
- Bacterial infections: Community acquired pneumonia, enteric fever 
The knowledge of the patient’s of comorbidities like diabetes, hypertension, 
cardiovascular disease, renal diseases are important in guiding treatment, as these conditions 
can be associated with poorer outcomes (63,64). Dengue infection can present with 
superadded bacterial infection, thus thorough history and examination is mandatory for a 
comprehensive management. Most patients present after the febrile period, which is when the 
manifestations of capillary leak and other severe features become more apparent (61).  
 
 
                Fig. 5: The WHO 2009 classification of Dengue fever 
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The WHO has divided the course of the illness into three phases: 
1) Febrile phase: This phase is associated with high-grade fever associated with myalgia, 
headache, retro-orbital pain, fatiguability, loss of appetite, flushing and a rash. It mimics 
undifferentiated viral fever and flu like illness. Some patients may have conjunctival 
injection, sore throat resembling a coryza. Patients may often not seek medical attention 
in this phase. 
2) Critical phase: This is the phase of organ dysfunction that starts with increased capillary 
permeability and all the other pathogenic mechanisms that have been discussed above. 
Not all patients will have a critical phase, but those who do might manifest the warning 
signs or progress to severe dengue.  
  The onset of the critical phase is usually heralded by defervescence with additional 
new symptoms, which are attributable to the capillary leak, thrombocytopenia and 
coagulopathy. With adequate therapy the disease progression can often be halted. 
However rarely severe disease ensues which is accompanied by multi-organ dysfunction 
and high mortality. An outline of the symptoms and organ involvement has been outlined 
in Fig. 5. The major manifestations can be: 
a) CNS: Dengue encephalopathy - Altered sensorium, seizures 
b) Liver dysfunction: Severe transaminitis jaundice 
c) Acute kidney injury: Pre-renal failure, acute tubular necrosis, and interstitial nephritis 
d) Bleeding: Coagulopathy, thrombocytopenia 
e) Respiratory distress: Pleural effusion, pulmonary edema, ARDS, secondary to 
myocarditis 
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A progressive drop in thrombocytopenia usually heralds the critical phase. This is usually 
accompanied by rising hematocrit, leukopenia, and transaminitis with tender 
hepatomegaly. All patients who reach this stage require in patient therapy with parenteral 
hydration, monitoring of cardio-respiratory and bleeding parameters and a close watch 
for any overt organ failure. 
3) Recovery phase: This phase marks the onset of remedial measures by the immune system 
towards homeostasis. There is a progressive improvement of platelet and leukocyte 
counts, couple with improvement in plasma volume and endothelial integrity. However 
an aftermath of the capillary leak might proceed onto the recovery phase, especially in 
those who have been aggressively resuscitated leading to persistent respiratory distress. 
Most patients however have a steady improvement in clinical and laboratory parameters. 
 
Laboratory diagnosis: 
  The laboratory diagnosis of dengue is based on either indirect evidence of the viral 
infection through serologies or direct assessment of viral RNA and proteins (Table 1) (61). 
The use of serology in the diagnosis of dengue is based on the understanding of the immune 
response to dengue infection and the duration of illness. Some markers are used for routine 
clinical purpose, while some are predominantly for research work.  
   The uses of these markers are guided by the duration of illness and resource 
availability. WHO has detailed the use of these diagnostic tests as mentioned in the following 
table: 
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Methodology 
Time to 
detection 
after infection 
Results 
turnaround 
time 
Direct detection of 
virus and viral 
products 
Virus isolation Cell culture: Mosquito 
based inoculation 
 
First week 
 
 
 
 
 
 
> 1 week 
 
 
 
 
 
 
 
 
Nucleic acid detection 
 
Antigen detection 
PCR based assays 
 
 
NS1Ag 
- Rapid card test 
 
- ELISA based assay 
Mostly from 
Day1 
1-2 days 
 
 
 
Few minutes 
to hours 
2-5 days 
Detection of 
serological response 
Single serum analysis 
 
 
 
 
Paired sera 
 
IgM and IgG detection: 
- Rapid card test 
 
- ELISA based assay 
 
Comparison of acute (1-
5 days) and convalescent 
sera (15-21 days) for 
IgM and IgG 
Mostly After 
Day 4 
 
Few minutes 
to hours 
2-5 days 
 
             Table 1: Direct and serological assessment of dengue infection 
The positivity and titres of the different tests also depend on primary vs. secondary dengue 
infection (65). Fig. 6 adapted from Peeling et al depicts the variable response of different 
serologies in primary and secondary dengue infection.  
 
 
 
Fig. 6: Serological response in primary and secondary dengue 
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The laboratory diagnosis of dengue infection is also guided by the purpose of testing: 
-  Individual case detection: Early vs. late 
-  Epidemiological surveillance 
-  Vaccine efficacy studies 
The modality used varies accordingly. The WHO in the guidelines of 2009 and 2012 have 
segregated the diagnostic tests according to the level of care and also categorized the 
interpretation of tests into confirmed and possible dengue infection. Table 2 and Table 3 
adapted from the WHO 2012 handbook of clinical management guidelines of dengue 
highlights the same. The uses of diagnostic tests are always a supplement to clinical diagnosis 
and to eliminate other disease differentials. Hence it is not always necessary especially when 
the clinical picture is sufficiently clear. Local disease epidemiology and cost benefits should 
be assessed before any diagnostic test is used routinely. 
 
ELISA = enzyme-linked immunosorbent assay; IgG = immunoglobulin G; IgM = immunoglobulin M; IHA = indirect 
haemagglutination; NS1 Ag = non-structural protein 1 antigen 
Table 2: Laboratory service level recommendation for diagnostic tests for dengue infection 
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ELISA = enzyme-linked immunosorbent assay; IgG = immunoglobulin G; IgM = immunoglobulin M; NS1 Ag = non-
structural protein 1 antigen; RT-PCR = reverse transcriptase polymerase chain reaction 
Table 3: Diagnostic tests and their role in diagnosis of dengue infection 
 
Management principles: 
  Different international and local bodies from time to time formulate management 
strategies and algorithms for management of dengue fever with the focus being on available 
resources and epidemiological patterns. The WHO latest in 2012 laid down guidelines for 
management of the different forms of dengue fever and its complications. These algorithms 
address the commonly faced problems and provide the backbone on which further titration of 
therapies should be done locally and by the attending physician on a case-to-case basis. The 
management principles are based solely on supportive care with early fluid resuscitation, 
organ support and rarely transfusion support. 
   In the febrile phase and those not progressing to the critical phase, patients can be 
managed on an outpatient basis. Adequate oral hydration should be ensured and patients 
should be warned about the danger signs that herald the critical phase. All patients who show 
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any of the danger signs ideally need admission for close monitoring. On of the commonest 
manifestation of the critical phase is shock. This closely accompanies organ dysfunction in 
the form of encephalopathy, ischemic hepatitis, respiratory distress and renal failure. The 
shock can be: 
- Transient compensated shock 
- Profound, prolonged uncompensated shock 
 
 In dengue, unlike other etiologies of septic shock, there is early and severe endothelial 
dysfunction coupled with the hypotension. This makes fluid resuscitation in shock 
challenging as it leads to third spacing and adds to ongoing respiratory distress and liver 
dysfunction. Cardiac dysfunction is has been often described in dengue infection and can 
range from mild tachycardia to severe myocarditis and cardiogenic shock (66,67) . This 
makes fluid resuscitation a closely orchestrated management, but all the same the most 
important of the supportive measures. In the non-severe forms of dengue oral hydration is 
often sufficient. However with the onset of more severe disease the added gastrointestinal 
symptoms leading to poor oral intake coupled with the severe intravascular depletion 
warrants parenteral hydration. Fluid resuscitation in severe dengue should be monitored 
considering the amount of third spacing, respiratory fluid overload and cardiac dysfunction 
that often accompanies the severe forms. Early and adequate fluid resuscitation might prevent 
organ injury, need for vasopressors and hospital stay. Serum electrolytes and renal function 
should be monitored while such therapies are continued. 
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The WHO guidelines classifies the management approaches into three groups of patients: 
- Group A: Patients with non severe disease with no warning signs, who adequately tolerate 
oral feeds, have no other contraindication to outpatient care and can come easily for follow 
ups. They form the crux of community-based care. 
- Group B: Patients who have warning signs and have high and early chance of progression 
to the critical phase. Pregnant patients, young children, elderly and those with comorbidities 
belong to this category. They warrant in-patient management and need parenteral fluids with 
close monitoring of organ systems. 
- Group C: Patients with severe dengue who have significant single organ or multi-organ 
dysfunction. They often require significant critical care and organ support. They are better 
referred to centres equipped to handle sicker patients. The mortality increases significantly 
with delayed identification of these patients. 
 Fig. 7 depicts the outlines of fluid resuscitation in patients with compensated shock. In 
accordance with other guidelines of care in shock, like the Surviving sepsis guidelines, goal 
directed therapy helps in preventing over-resuscitation and worsening cardio-respiratory 
parameters. (68).  All patients should be examined for superadded infections that might co-
exist over and above the dengue infection and might need broad-spectrum antibiotics if a 
focus is found (69). Certain scoring systems, like the DDIS (Dengue Dual Infection Score) 
has been constructed to diagnose early patients with superadded bacterial infection (70). As 
thrombocytopenia and coagulopathy are common in severe dengue, any major clinical 
bleeding or significant/progressive drop in hemoglobin should warrant transfusion. 
Transfusion guidelines for platelets by the NVDCP India have been highlighted before.  
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Fig 7: Algorithm for management of compensated shock in adults with dengue fever. Adapted form 
the WHO 2012 guidelines on management of dengue 
 
   The specifics of organ support and transfusion have been dealt with by the WHO and 
modified by local guidelines. In principle, management of dengue fever requires proper 
classification of patients into different risk groups, assessment of early signs of severity and 
protocol based management of shock and other complications. Transfusion of platelets and 
packed cells are reserved for special conditions and rampant use of antibiotics is not 
warranted. Early referral to higher centres is prudent in cases with severe dengue. 
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The signs of adequate resuscitation and progress to the recovery phase in patients with severe 
dengue can be manifested as the following: 
- Improvement in blood pressure and reduction in heart rate 
- Improvement in urine output and normalisation of electrolytes, creatinine if had been 
deranged before 
    - Reduction in transaminitis  
    - Normalisation of hematocrit and improvement in platelet counts 
    - Improvement in sensorium 
    - Reduction of abdominal pain and improvement in appetite 
If the achievements of these variables are delayed, a superadded infection or other pathology 
should be considered. Clinical improvement in dengue is usually steady and any worsening 
after initial improvement should arouse suspicion of secondary pathologies. 
 
    In pregnant dengue patients, as has been already mentioned; the disease can be often 
severe with early capillary leak, respiratory distress and hypotension. Disease severity can 
vary with the pregnancy trimester, with studies showing increased evidence of preterm 
delivery and low birth weight in infections prior to third trimester. Ruling out pregnancy 
related morbidities like hyperemesis gravidarum, severe pre-ecclampsia and HELLP 
syndrome should be ruled out, as a lot of symptoms like vomiting, pedal edema, respiratory 
distress, altered sensorium, thrombocytopenia, renal failure, dyselectrolemia and 
transaminitis are shared by these conditions. In the presence of resources it might be better to 
admit and manage these patients. There is no difference in the fluid management between  
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pregnant patients and others. If delivery is inadvertent, platelets and other blood product 
support may be required. All pregnant women with dengue infection in their last trimester 
should be treated as a high-risk pregnancy. 
 
            Disease outcome assessment:  It has been discussed above in detail show the dengue 
fever is classified based on its severity, the clinical care groups and models of management. 
However these classification systems though helpful in designing management algorithm fail 
to prognosticate adequately. Several scoring systems such as SOFA (Sequential organ failure 
assessment), APACHE II (Acute physiology and chronic health evaluation) and others have 
been used to assess dengue severity especially in ICU patients.  Individual immunological 
markers, laboratory parameters alone or isolated organ failure assessment might not depict 
the entire picture (71). Scoring systems that include clinical and laboratory parameters may 
be able to assess better the status in severe dengue with a higher prognostic yield. There is no 
uniform accepted prognosticative scoring system available for dengue fever. Lee et al used a 
retrospective cohort of 69 patients with severe dengue and 1184 patients with non severe 
dengue from Taiwan and made scoring systems for early assessment of severity in dengue 
(72). Validations of the same in other cohorts are awaited.  
    Amâncio et al in a series of 97 patients from Brazil admitted to the ICU with dengue 
fever found that those with lower albumin, elevated creatinine, leukocytosis and elderly had 
an increased mortality (73). They also showed the utility of SOFA and APACHE II scores 
and found higher scores to co-relate with in-hospital mortality. Jog et al from India in a  
retrospective study of 113 patients with dengue fever and at least 2 organ dysfunction 
according to SOFA, found low serum albumin, high arterial lactate levels and SOFA scores  
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correlated with mortality (74). This study did not include pregnant women. In a retrospective 
study of 4787 patients with dengue admitted to the ICU from Taiwan, Chen at al showed that 
lower GCS scores, thrombocytopenia and higher APACHE II scores among other variables 
were associated with increased mortality (69).  Smaller prospective studies also from Taiwan 
had shown female gender, prolonged aPTT, higher levels of transaminitis and cardiac arrest 
before hospital admission to be associated with increased mortality (75). Thus many 
parameters in different studies have been shown to correlate well with outcomes, especially 
in sicker patients, however scoring systems like APACHE II and SOFA may be more 
consistent in dynamic assessment of status and prognostication. 
 
     The road ahead:  Despite increasing idea about the epidemiology, virology, 
immunopathogenesis, and better diagnostics with management, dengue infection is a global 
health burden with hyperendemicity in South East Asia. Its toll on healthcare costs is huge. 
Prevention of infection is the ultimate goal and can range from vector control measures, 
better protection from mosquito bites to vaccination. Much study is going on about the latter , 
with newer epitopes being recognized that are relatively more conserved across the different 
serotypes thereby promising to be vaccine targets. The current vaccine approaches against 
dengue include (24,76): 
1) Live attenuated viruses: 
    - Viruses attenuated by cell culture or mutagenesis 
   - Chimeric live viruses (Yellow fever-dengue chimera, Dengue-dengue intertype chimera) 
2) Inactivated and pure whole virion 
	 44	
 
3) Recombinant subunit proteins 
4) DNA vaccines 
5) Virus like particles 
6) Viral vectors expressing DENV antigen 
 
 These vaccines are at different phases of study with some having made remarkable 
progress, though none have yet been licensed or included in the management guideline. It is 
probably a matter of time when efficient and potent vaccines will be included in guidelines 
and readily available. The road ahead in dengue management is promising though much 
research still needs to be done to both disease prevention and to optimize management 
especially in the severe forms of the disease. 
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Materials and Methods 
 
Study setting and duration:   
 
This study was conducted in Christian Medical College and Hospital, Vellore, a tertiary care 
teaching hospital in South India with around 2700 beds. The hospital serves the population of 
Tamil Nadu and the neighboring state of Andhra Pradesh, besides being a referral center for 
patients from other parts of the country and the Indian subcontinent.  
Patients were recruited for this study from May 2016 to August 2017. As the present study 
is dependent of seasonal variations we expected to recruit significant numbers over the 
stipulated time period as mentioned above. The study recruited patients from the following 
departments in our hospital: 
• Department of Medicine 
• Department of Accident and Emergency Medicine 
• Medical Intensive care unit 
 
Study design: 
 This is a prospective study aiming to look at the association of ADAMTS 13 levels and 
vWF activity to dengue severity and outcomes. It was approved by the Institutional review 
board (Blue) and the Ethics committee prior to its initiation. (Annexure 1) 
	 46	
 
Study participants: 
Selection set: All adults (Age >18) who present with an undifferentiated acute febrile illness 
with thrombocytopenia (Platelet count on Coulter < 1,00,000/cu mm)   
Inclusion criteria: All individuals in the above set who are tested positive for Dengue IgM/ 
NS1 Antigen.   
Exclusion criteria:   
1) All individuals from the “Selection” set who are negative for both Dengue IgM and 
NS1Ag.   
2) All individuals from the “Selection” set who have any diagnosed hematological condition  
3) All individuals from the “Selection” set who have received any form of transfusion from 
the onset of fever to presentation   
4) All individuals from the “Selection” set who are seropositive for HBV, HCV or HIV.   
5) All individuals from the “Selection” set who have any known autoimmune condition/ 
 collagen vascular disease/ prior or present malignancy/ diagnosed chronic liver disease/ on 
Aspirin, Clopidgrel, other antiplatelets/ Warfarin, Acitrom, other anticoagulants   
6) All individuals from the “Selection” set who have an eschar   
 The present study did not necessitate controls as the comparison was done amongst 
the study population with different severity of dengue fever. 
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Case definition and ascertainment: The WHO 2009 definition was used for initial case 
selection as “probable dengue” and was included in the selection set as mentioned above. 
Once they were tested positive for NS1 antigen or IgM for Dengue, they were included in the 
study.  
Data sources and collection: For all patients from the “ Selection” set blood samples were 
collected for ADAMTS 13 assay and vWF collagen activity at presentation, while the 
demographic and clinical data were noted. The individuals who tested positive for Dengue 
IgM/ NS1Ag had the samples processed for the above. Ward/ OPD/ casualty notes and daily 
direct assessment by the principal investigator was used for following up the patient. 
The demographic and clinical data was collected on a clinical pro-forma validated by the 
participating departments and the Institutional review board. Follow up of those individuals 
who get admitted were done as following:  
1) SOFA (Sequential organ failure assessment) score at admission  and during their follow 
up till convalescence 
2) Total transfusion support needed (Separate cumulative for Packed red cells/ Platelets  as 
Platelet rich concentrate / Fresh  Frozen plasma/ Cryoprecipitate)   
3) Organ supports needed during admission  : Renal replacement therapy  : Ventilatory support 
as - 1) Non invasive 2) Invasive  etc. 
4) Outcome: Death/ Discharge- Cured/ Against medical advice  
	 48	
 
Outcome Assessment:  
Primary outcome:  To estimate the levels of ADAMTS 13 levels and vWF activity in 
adults with dengue fever at presentation and compare it to disease severity  by the highest 
SOFA score documented in the subjects 
Secondary outcomes:		
1) To assess if the severity of thrombocytopenia at presentation is correlated with 
 ADAMTS-13 level and vWF collagen activity. Such correlation may suggest a  mechanism 
for the thrombocytopenia   
2) To assess if severity of illness is correlates with ADAMTS-13 level and vWF activity.   
3) To determine if low ADAMTS-13 level and vWF activity are associated with  increased 
mortality   
4) To analyze ADAMTS-13 levels and vWF collagen activity in pregnant individuals  with 
dengue and compare their levels with non-pregnant individuals with dengue   
Sample size: The required sample size to show that SOFA score will correlate with 
ADAMTS13 and VWF was found to be 103 subjects with a power of 80%, 5% level of 
significance and an anticipated correlation of about 0.7 between the two measures. As there is 
no study mainly focused to look at the correlation of SOFA scores with ADAMTS 13 and 
VWF, however, as it was expected to be good, the anticipation of correlation was considered 
to be 0.75 (55) .  
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Study Algorithm: 
	
 
 
All patients with fever and thrombocytopenia and 
probable dengue (Platelets < 1,00,000/ cu mm on 
the Coulter count value) 
Analyse	inclusion	and	exclusion	factors		 Assess:	- Demographics	- Comorbidities	- Risk	factors	- Other	available	clinical	and	laboratory	parameters	
ADAMTS 13 assay to be done and vWF collagen activity 
to be assessed for only those individual who test positive 
for Dengue NS1Ag/ IgM:                           
n=103 
Routine investigations plus 
Dengue IgM and NS1Ag in individuals with high clinical suspicion 
of dengue fever 
Additionally: Samples collected for ADAMTS 13 and vWF activity 
assay measurements 
	a) Correlation	of	disease	severity	by	SOFA	scoring	in	those	who	need	admission	and	overall	outcome	when	compared	to	their	levels	of	ADAMTS	13	and	vWF	collagen	activity	at	presentation	b) Correlate	levels	of	ADAMTS	13	and	vWF	collagen	activity	to	the	levels	of	thrombocytopenia	c) Assess	these	levels	in	pregnant	females	with	dengue	and	compare	it	to	non	pregnant	individuals	with	dengue	fever		
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Assessment of laboratory variables: 
ADAMTS 13 assay: 
ACTIFLUOR ADAMTS13 activity assay is a fluorescence resonance energy transfer 
(FRET) assay for measurement of ADAMTS13 in human plasma. Principle: The assay 
measures the amount of ADAMTS13 activity in human plasma (citrated sample) using 
recombinant VWF86-ALEXA FRET substrate. Proteolytic cleavage of the VWF86-ALEXA 
FRET substrate between Tyr/Met residues by ADAMTS13 uncouples ALEXA 
fluorochromes resulting in increased fluorescence. The increase in Fluoroscence over time 
(Vmax) is monitored at 37 C using spectroflurometer (Ex =485nm; Em = 535nm) A standard 
curve is constructed using normal plasma with a known concentration of ADAMTS13 
(provided in the kit). The activity in the plasma is determined by interpolation of the Vmax 
values from the standard curve.  
Reagents:   
• 6x8 fluorescence microwell strips plus frame (white)  
• 2 vials of ADAMTS13 standard, 250ul  
• 1 vial of positive control  
• 1 vial of DMSO  
• 1 vial of ALEXA488-VEF86 FRET substrate  
• 2 vials of Assay buffer  
• 3 vials of ADAMTS13 inactivated plasma  
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Von Willebrand Factor collagen binding activity (vWF: CBA): 
To estimate the Collagen binding assay level in citrated plasma by using ELISA method:   
Principle: The assay tests the ability of patient plasma derived from von Willebrand factor to 
bind collagen, which has previously been coated onto 96 well plates. Low VWF: CBA levels 
will be present in individuals with either quantitative defects or with qualitative defects.  
Sample: Citrated sample.  Samples and control run in duplicate.  Quality control: Normal 
control (pooled normal plasma) and low levels abnormal control (Dade P). 
 Normal values: 50-400%  
Data entry and statistical analysis:  
All data were entered into the clinical proforma and subsequently into EpiData 
software. The data was extracted onto Microsoft Excel and analysed by IBM SPSS software. 
Univariate Analysis -For the normal data, we did independent T-test and for the non-normal 
data, Mann-Whitney U test by the outcome variable based on dengue severity. For the 
variables that were significant on univariate analysis we did a multivariate analysis by 
logistic regression. 
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Results 
This prospective observational study was conducted from May 2016 through August 
2017. During this period 105 patients met the selection criteria. Of these 105, 74 had 
confirmed dengue, of which 12 were excluded according to the exclusion criteria as 
mentioned above. A total of 62 patients were included for whom the ADAMTS 13 and vWF: 
CBA was processed and the data was used for final analysis. Fig. 8 describes the STROBE 
diagram for the present study. Due to seasonal and yearly variation in the incidence of dengue 
cases, the required number of patients as mentioned in the sample size calculation could not 
be met in the present study.  
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Fig. 8: STROBE diagram of AVID study 
Met	Selection	criteria	
N=	105	
Positive	for	NS1Antigen	and/or	IgM	Dengue	(meeting	Inclusion	criteria)	
N=	74	
Final	cohort	of	patients		
N=62	
Excluded:	
9:	Transfused	outside	
2:	On	antiplatelets	
1:	HIV	positive	
NS1Ag	positive	only=	
12		IgM	dengue	positive	only=	17		Both	positive=	33		
Non	severe	dengue	with	no	warning	signs=	15		Non	severe	dengue	with	warning	signs	=	36		Severe	dengue=	11	
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Baseline characteristics:  
 
   The cohort consisted of 62 patients who presented in the above mentioned time period 
with an acute febrile illness, thrombocytopenia with a platelet count of less than 1 lac/cu mm 
and tested positive for NS1 antigen or Dengue IgM. Of the 62 subjects who were included for 
the final analysis there were 40 males (64.5%) and 22 females  (35.5%), showing a clear male 
preponderance. The median age was 22 years (Range 16-84 years) reflecting larger 
epidemiological studies. Majority of the male subjects were unskilled or semi-skilled 
labourers while most of the female subjects were homemakers. Majority of the patients had 
no known comorbidities. Four patients (6.4%) had Type 2 Diabetes, 3 (4.8%) had essential 
hypertension of which 2 had both the above. None of the patients had any prior history of 
prior dengue infection and none of them had received any form of transfusion prior to their 
inclusion in the study. None of them had any significant history of prior bleeding diathesis or 
any family history of the same. No patients had any significant history of substance abuse.  
   Eight patients (12.9%) were managed on an outpatient basis (OPD or Casualty) while the 
remaining 54 patients (87.1%) patients were admitted for further management. The median 
days post symptom onset after which the patient presented was 5 (2-15 days). We considered 
fever, myalgia or any complaint attributable to the dengue infection as symptom while 
calculating the date of presentation. Thirty-two patients (51.6%) were afebrile at the time of 
presentation to our centre. Forty-eight patients (77.4%) did not have any complaints of 
bleeding manifestation at presentation, while 14 patients (23.6%) had some form of bleeding. 
We considered oral (mucosal), nasal and injection site bleeding as minor bleeding diathesis,  
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while hemoptysis, hematemesis, hematuria, maleana/haemtochezia as major bleeding 
manifestations. Six patients (9.6%) had major and 8 (12.9%) had minor bleeding 
manifestations. Table 4a and 4b elaborates the demographic and clinical findings at 
presentation respectively. 
 
 
Parameters Median/ N (Range) {%} 
Age 22 (18-64) 
Gender distribution 
                    Males 
                    Females 
 
40 {64.5} 
22 {35.5} 
State of residence 
                    Tamil Nadu 
                    Andhra Pradesh 
                    Others 
 
44 {70.9} 
10 {16.1} 
  8 {13} 
Co-morbidities 
                    Diabetes mellitus 
                    Systemic hypertension 
                    Both 
 
2 {3.2} 
1 {1.6} 
 2 {3.2} 
Substance abuse Nil 
Prior dengue infection Nil 
Prior transfusion Nil 
Prior history or family history of bleeding 
diathesis 
Nil 
 
Table 4a: Demographic characteristics of study subjects 
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Clinical parameters Median value (Range) {%} 
Day of presentation post symptom onset 5 (2-15) 
Subjects afebrile at presentation 32 {51.6} 
Bleeding manifestation: 
                                                 Minor  
                                                 Major 
14 {23.6} 
  8 {12.9} 
  6 {9.6} 
 General Symptomatology at presentation: 
Headache 
Myalgia 
Fatiguability 
 
60 {96.7} 
62 {100} 
62 {100} 
Respiratory symptoms: *  
Cough 
Breathlessness 
Chest pain 
15 {24.2} 
13 {21} 
 7 {11.3} 
 1 {1.6} 
Gastrointestinal symptoms: * 
Nausea/vomiting 
Loose stools 
Abdominal pain  
38 {61.3) 
33 {53.2} 
13 {21} 
16 {25.8} 
CNS symptoms: *  
Altered sensorium 
Seizures 
1 {1.6} 
1 {1.6} 
0 {0} 
Miscellaneous symptoms: 
Decreased urine 
output 
 
0 {0} 
 
Table 4b: Symptomatology at presentation 
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Fig. 9: Bar graph depicting the frequencies of symptoms at presentation 
  
 As is visible from the above bar diagram, most patients had GI symptoms in the form of 
nausea/vomiting, loose stools followed by respiratory symptoms. However almost all patients 
had headache while all patients complained of some form of myalgia and fatiguability at 
presentation.  
 All patients at admission were evaluated by the attending physician and vital signs and 
detailed clinical examination done. Most patients had tachycardia at presentation with a 
median pulse rate of 93/min (68-130 beats /minute). The median systolic blood pressure at 
presentation was 100 mm of Hg (70-130 mm of Hg) and diastolic blood pressure of 60 mm of 
Hg (50-90 mm of Hg). Table 5 depicts the clinical findings at presentation documented at 
admission.  
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Clinical parameters/findings Median value (Range) {%} 
Heart rate (beats/min) 93 (68-130) 
Blood pressure (mm of Hg): 
SBP 
DBP 
 
100 (70-130) 
  60 (50-90) 
Respiratory parameters: 
Rate (per minute)  
Saturation (% in room air) 
 
 20 (14-40) 
 98 (88-100) 
Dermatological manifestation: 
Erythematous rash 
Petechiae/Ecchymotic spots 
 
55 {88.7} 
  2 {3.2} 
Respiratory findings: 
Positive findings # 
Pleural effusion (reduced air entry) 
Crackles 
Increased conducted sounds 
 
 9 {14.5} 
 9 {14.5} 
 2 {3.2} 
 2 {3.2} 
Abdomen findings:  
Positive findings # 
Free fluid 
Guarding 
Tenderness 
 
 
11 {17.7} 
  7 {11.3} 
  1 {1.6} 
  9 {14.5} 
CNS findings:  
Positive findings # 
Altered sensorium 
 
 
 1 {1.6} 
    1 {1.6} 
 
Table 5: Clinical findings at presentation 
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Fig. 10: Bar graph depicting the frequency of positive findings at presentation 
 
 All patients had basic blood investigation including complete blood count (CBC), renal 
and liver function tests, serum electrolytes at admission. Some patients had coagulation 
parameters, blood cultures and other serologies (Scrub typhus, leptospira IgM) according to the 
clinical presentation. Most patients had urinalysis and a chest skiagram. Malarial smears were 
done for all patients. As mentioned above the diagnosis of dengue was based on positivity for 
NS1 Antigen or IgM dengue positivity. Both of these were done for all patients together with 
IgG dengue. Further investigation as mandated by the clinical findings and the physician’s 
discretion were conducted. Table 6 provides the baseline investigations at presentation/ 
enrollment of our study subjects. Investigations were repeated as required during their course of 
treatment and will be discussed below.  
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Laboratory parameters Median value/(Range) {%} 
Hemoglobin (gm/dl) 14.45 (3.5-19.2) 
Total WBC (per cumm): 
Neutrophils (% of WBC) 
Lymphocytes (% of WBC) 
Monocytes (% of WBC) 
4350 (1700-37,600) 
60 (23-92) 
25 (2-64) 
  9 (2-29) 
Platelet (per cumm): 
Automated via Coulter 
Manual on smear  
 
31000 (4000-95,000) 
41000 (4000-95,000) 
Creatinine (mg/dl) 0.90 (0.45-2.18) 
Serum electrolytes:  
Sodium (mmol/L) 
Potassium (mmol/L) 
 
134 (125-142) 
3.8 (2.8-5.7) 
Liver function tests: 
Total bilirubin (mg./dl) 
Direct bilirubin (mg./dl) 
Total protein (gm./dl) 
Serum albumin (gm./dl) 
SGOT (IU/L) 
SGPT (IU/L) 
ALP (IU/L) 
 
1.23 (0.2-9.1) 
1.06 (0.1-7.8) 
6.6 (4.2-8.3) 
3.6 (1.8-4.7) 
193 (23-6860) 
93 (12-2958) 
71 (34-361) 
 
Table 6:  basic laboratory parameters at presentation 
 
  A majority of patients presented with hemoconcentration and normal to low WBC counts. 
The median platelet count on automated counters was 31,000/cu mm, which was lower than 
when checked by manual smear count. Hyponatremia was common and more than 90%  
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patients had transaminitis, the SGOT being universally more than SGPT in our cohort of 
patients. Proteinuria (not shown in the above table) was the most common abnormality on 
urinanalysis, accounting in 60 patients (96.8%). Hematuria and pyuria were rare observed in 
3 and 2 patients respectively.   
 Chest skiagram was done in all patients with 47 patients (74.2%) having a normal 
image, 7 (11.3%) having pleural effusion, 5 (8.1%) opacities and 4 (6.5%) having non-
specific bilateral infiltrates. USG of the abdomen was done in 17 patients (27.4%) with 12 of 
them (19.4%) showing free fluid. The usual triggers for USG abdomen included severe 
abdominal pain, significant tenderness/guarding, persisting loose stools or persisting fever. 
The following pie chart shows the distribution of serology positivity fro dengue in our 
patients.  
 
 
    Fig. 11: Pie chart depicting the different combination of dengue serology positivity in study subjects 
7	
3	 2	
5	
15	
30	
Only	NS1Ag	NS1Ag	+IgM	Only	IgM	Ns1Ag	+	IgG	IgM+IgG	NS1Ag+IgM+IgG	
	 62	
 
   
 Pregnant subjects: 
  
 In the present study we aim to assess the differences in ADAMTS 13 levels and 
vWF:CBA in pregnant women with dengue when compared to the no pregnant dengue 
women. A total of 6 patients (9.6%) were pregnant at the time of study enrollment. 4 women 
were primigravida while 1 each were gravida 2 and gravida 3. One woman presented in the 
first trimester at 8 weeks, 2 women in the second trimester (weeks 16 and 18) and 3 women 
in their third trimester (weeks 32,34 and 38). None of them had any prior pregnancy related 
complications or any present pregnancy related comorbidities. Table 7 provides the baseline 
characteristics of the above subjects.  
 
Parameters Median value/N (Range) {%} 
Number of pregnant women with dengue 6 (9.6% of patients, 27.2% of female 
patients) 
 
Age (in years) 25 (21-36) 
Gestational score: 
Gravida 
 
1 (1-3) 
Gestational age: 
First trimester 
Second trimester 
Third trimester 
 
1 
2 
3 
 
Table 7: Baseline characteristics of pregnant patients with dengue 
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Outcomes:  
 
 For all patients we assessed the SOFA score at the time of presentation or enrollment. 
Patients who had presented already prior to the define thrombocytopenia cutoff, were 
enrolled once the platelet counts dropped to less than 1 lac/ cu mm provided they fulfilled all 
the other criteriae. The SOFA score was calculated everyday during their period of treatment 
for the dengue infection based on the latest available laboratory values and daily clinical 
examination. The highest SOFA scores attained by each subject were also calculated. 
 We did univariate analysis to look at factors that had a significant association with 
dengue severity. We used dichotomous outcomes to do the same by clubbing non-severe 
dengue with warning signs and Severe dengue as “More severe dengue” and non-severe 
dengue without warning signs as “less severe dengue.” From the univariate analysis we chose 
factors that appeared significant and used a multivariate analysis.  
 The following factors were looked at: 
1) Association between ADAMTS13 levels to dengue severity and highest SOFA scores  
2) Association of any positive systemic sign to disease severity 
3) Association of initial and lowest platelet values, highest transaminitis documented, need 
for ICU care to disease severity 
4) Gender specific difference between ADAMTS 13 levels 
5) Difference in ADAMTS13 levels between pregnant and non pregnant females 
Table 8 provides the baseline levels of ADAMTS 13 and vWF:CBA, SOFA scores at 
presentation and highest SOFA scores.  
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Parameters Median value/N (Range) {%} 
ADAMTS 13 (%) 76 (22-121) 
vWF:CBA (%) 135  (38-309) 
SOFA scores: 
At presentation 
Highest SOFA 
 
3 (2-8) 
4 (2-21) 
Liver enzymes: 
Highest SGOT (IU/L) 
Highest SGPT (IU/L) 
 
246 (40-6860) 
138 (18-2958) 
Lowest platelet (per cu mm)  17,000 (4000-78,000) 
 
Table 8: Baseline ADAMTS 13 and vWF:CBA values with certain outcome parameters 
 
 
 SOFA was used in our study for initial assessment of disease severity. However, 
as it includes thrombocytopenia as one of the parameter and thrombocytopenia 
happens to be a disease manifestation of dengue, with the present inclusion criteria 
including patients only with platelet count less than 1 lac/cu mm, all patients at least 
had a SOFA score of 2 at presentation.  However the daily use of SOFA score as a 
dynamic monitoring tool and correlation of highest SOFA attained in subjects to 
outcome might undermine this caveat.  The following tables and diagrams depict the 
proportion of non-severe and severe dengue in our study, overall outcomes, organ 
system involvement, transfusion requirement and mortality.  
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Parameters N {%} 
Acute kidney injury 
Requirement of RRT 
11 {17.7} 
  1 {1.6} 
ICU care   4 {6.4} 
Vasopressor requirement   2 {3.2} 
Respiratory support    3 {4.8} 
Transfusion requirement 
Platelets 
Packed red cells 
Fresh frozen plasma (FFP) 
Cryoprecipitate 
17 {27.4} 
16 {25.8} 
  3 {4.8} 
10 {16.1} 
  2 {3.2} 
RRT: Renal replacement therapy (Hemodialysis/ ultrafiltration), ICU: Intensive care unit 
Respiratory support included all forms of positive pressure ventilation, invasive and non-invasive 
 
Table 9: Outcome parameters in our cohort of patients 
 
   Despite having a larger proportion of patients with severe dengue only about a 
quarter of patients required any form of transfusion support. Platelets were most commonly 
transfused. While the median value of platelets transfused were 0 units, the maximum 
platelet requirement were 17 units of random door platelets. The median units of FFP 
transfused were also 0 while the maximum transfused to patient was 20 units. In our 
institution guidelines have been laid for transfusion in dengue patient, which usually 
includes, but is not limited to 
• Ongoing major bleed with significant thrombocytopenia 
• High grade fever/ shock with platelets less than 10,000/cu mm 
FFP / cryoprecipitate requirement were guided by the levels of coagulopathy. 
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Fig 12: Pie diagram depicting the point of management of our patients 
 
 
 
Fig 13: Pie chart depicting the dengue cases according to the WHO grading for severity 
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 Overall in our study, out of the 62 patients, 60 (96.8%) were cured discharged. Two 
patients (3.2%) succumbed to the disease. One patient, a 48-year-old lady had presented with 
severe dengue in hypotension but had shown improvement with resuscitation and non-
invasive positive pressure ventilation due to ensuing respiratory distress. On Day 2 of her 
admission she had a sudden cardiac arrest, probably due to an arrhythmia and could not be 
resuscitated. The second patient was an 18-year-old girl, who presented with manifestation of 
severe dengue, (hypotension, respiratory distress and altered sensorium). She was intubated, 
admitted in ICU and succumbed to progressive respiratory compromise and superadded 
infection. We presume the second patient had a superadded bacterial respiratory infection at 
presentation, and was started on adequate antibiotics. Both patients had presented late into 
disease onset and after prior treatment at other hospitals. Table 10 highlights some important 
parameters of the two deceased patient in our study. 
  The median duration of hospital stay in our study for the patients who were admitted were 
4 days (3-30 days). For most patients with thrombocytopenia, we usually discharge once the 
platelet counts start to show an increment with amelioration of other major symptoms. 
Patients followed up in the outpatient department had at least one follow up after 
normalisation of platelet counts and symptom amelioration.  
   
Parameters Patient 1 Patient 2 
Age/Gender 48/female 19/female 
Comorbidities Nil Nil 
Date of presentation 10 14 
Temp Afebrile Afebrile 
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Clinical manifestations: 
 
Myalgia, headache 
Rash/ Vomiting 
Progressive 
breathlessness in ward 
 
Myalgia, headache 
No rash, vomiting 
Breathlessness  
Altered sensorium 
Clinical findings: Pulse-112/min 
BP- 100/60 mmHg 
RR-30/min, Sat- 96% 
RS/PA/CNS/CVS: 
Normal 
 
Pulse-119/min 
BP-94/60 mmHg 
RR-34/min Sat-90% 
R/S: Bilateral mild 
pleural effusion 
CNS: Altered 
Laboratory parameters: 
Hb (gm/dl) 
Total WBC (/cu mm) 
Initial platelet count (/cu mm) 
Initial creat (mg/dl) 
Initial Total/direct bilirubin 
(mg/dl) 
Initial SGOT/SGPT (IU/L) 
Dengue serology 
 
Day1 SOFA 
Highest SOFA 
Highest SGOT/SGPT (IU/L) 
AKI/RRT 
Transfusion requirement 
Respiratory support 
ICU care 
ADAMTS 13 
vWF:CBA 
 
17.2 
7400 
17000 
1.94 
1/0.4 
 
2800/920 
NS1Ag/IgM/IgG + 
 
6 
7 
2800/920 
Yes/No 
Yes 
Yes (Non invasive) 
Yes 
24.2 % 
180.5% 
 
10.8 
37600 
47000 
1.7 
9.1/7.8 
 
1284/400 
IgM/IgG + 
 
8 
21 
1287/400 
Yes/Yes 
Yes 
Yes (Invasive) 
Yes 
22.8 % 
297.5% 
 
Table 10: Clinical data and laboratory parameters of the 2 deceased patients in our study 
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Analysis of outcomes: 
 
  The statistical methods used for analysis have been described before.  We looked at 
demographic parameters, presence of comorbidities, clinical manifestation and their 
association with dengue severity. We also looked at how levels of ADAMTS affected dengue 
severity, the highest SOFA scores and lowest platelet values. As the mortality was very low, 
statistical analysis of factors affecting mortality could not be analysed in the present study. 
       None of the demographic parameters showed any significance to disease severity. 
Presence of any erythematous blanching rash at presentation had an association with disease 
severity. The other clinical symptoms were not significantly associated. The subsequent 
tables will depict the significance of different demographic, symptoms, signs and laboratory 
parameters to dengue severity.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 11a: Depicting the significance of demographic parameters and clinical symptoms to dengue 
severity on univariate analysis 
Parameters p value Parameters p value 
Gender 1 Abdominal pain 0.088 
Type 2 DM 0.564 Nausea/vomiting 0.136 
Hypertension 0.8 Loose stools 0.493 
Erythematous rash 0.008 CNS symptoms 1 
Bleeding  0.2 Petechiae 1 
Cough 0.159 
Breathlessness 0.180 
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Blanching rash seemed to herald a more severe form of dengue with an OR of 17 (95% CI= 
1.9-66.5). Lower systolic/diastolic blood pressure, respiratory rate at presentation were not 
associated with increased dengue severity. 
 
Parameters p value 
Ascites  0.18 
Abdomen tenderness 0.098 
Pleural effusion 0.1 
 
Table 11b. Abnormal clinical findings and their association with dengue severity on univariate 
analysis 
 
 We evaluated multiple laboratory and outcome parameters and analysed their association 
with dengue severity. On univariate analysis, the following parameters had a significant odds 
ratio:  
• Platelet count at presentation 
• Lowest platelet values 
• Urea at presentation 
• Total and direct bilirubin (TB/DB) at presentation 
• Highest SGOT and SGPT levels 
 
 
Parameters p value Parameters p value 
Platelet counts at 
presentation 
0.001 SGOT/SGPT 
(highest) 
0.001/0.008 
Lowest platelet 
counts 
0.001 TB/DB at 
presentation 
0.001/0.021 
Urea 0.002 
 
Table 11c: Basic laboratory parameters and its association with disease severity on univariate 
analysis 
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   Other factors like hemoglobin at presentation, total WBC counts, serum electrolytes, 
serum albumin did not have a significant bearing on disease severity. Presence of proteinuria 
appeared to be significant (p=0.010). We also evaluated the presence of acute kidney injury, 
need for transfusion requirement and vasopressor use, Day 1 and highest SOFA scores to 
disease severity. On factors significant on univariate analysis we did a multivariate analysis.  
 
Parameters p value Parameters p value 
SOFA Day 1 0.0001 AKI/RRT 0.039/1 
SOFA highest 0.0001 Transfusion 
support 
0.048 
ICU care 0.247 Vasopressor 
requirement 
1 
 
Table 11d: Monitoring score and organ failure scores and their association with dengue severity on 
univariate analysis 
 
 SOFA values both on Day 1 and the highest SOFA obtained by each patient strongly 
associated with the severity of dengue. The presence of an acute kidney injury at any point or 
the requirement of any form of transfusion support was also associated with more severe 
disease.  Finally neither ADAMTS 13 values on the day of presentation/enrollment, nor 
pregnancy had any bearing on disease severity. ADAMTS 13 values were also not 
significantly associated with the lowest platelet count achieved. Though a negative  
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correlation existed between ADAMTS 13 values and the highest SOFA score, it was not 
statistically significant. Fig 14a and 14b depict the scatter plots showing the relation of 
ADAMTS 13 to lowest platelet and highest SOFA respectively. 
 
 
                           Fig 14a 
 
 
Fig 14b 
   
Fig 14a and 14b: Scatter plots depicting the association of ADAMTS 13 values with the lowest 
platelet counts and highest SOFA scores 
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Fig. 15: Box plot diagram showing no significant difference in ADAMTS 13 levels between 
the less and dengue severity (DenSeverity) 
 
    Summarizing, ADAMTS 13 levels did not have any association with dengue severity, 
lowest platelet levels attained or the highest SOFA scores. However higher levels of 
ADAMTS 13 were associated with lesser transfusion requirement: OR of 0.97 (95% CI: 
0.94-0.99, p= 0.02). 
    We also analysed the role of dengue diagnostic serology in predicting disease severity. 
Presence of IgG positivity was not associated with increased dengue severity, nor was any 
combination of NS1Ag or IgM positivity. Though secondary dengue infection has been 
described to be more commonly severe, our study failed to show the same based on IgG 
positivity.   
 In the following table we discuss the factors described above that were significant on 
multivariate analysis. 
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Parameters  Odds ratio (OR) 95% C.I 
Rash 11.25 1.9-66.5 
Proteinuria 5.4 1.5-18.8 
SOFA Day 1 4.7 1.87- 12.2 
Total bilirubin 
(On day of presentation) 
133.1 4.6-3852.3 
 
Table 12: Parameters significantly associated with dengue severity on multivariate analysis 
 
   As depicted in the preceding table SOFA on Day 1 was associated with dengue severity. 
The wide confidence intervals were secondary to the small numbers in our study. Certain 
other parameters like highest levels of transaminitis also showed an association but were not 
statistically significant on multivariate analysis. All these factors have been previously 
showed to predict dengue severity and negatively affect outcomes. 
   
Analysis of pregnancy related factors: 
   Pregnancy was not associated with increased dengue severity. Comparison of ADAMTS 
13 values between pregnant and non-pregnant women did not show any difference. The 
median ADAMTS 13 level was 70.3 (60.4-113.9), compared to 78.65 (22.8-121.9) in non-
pregnant women with dengue. However with only 6 pregnant women in our cohort of 
patients it is impossible to come to any form of significant conclusion. 
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Discussion 
 
   The present study though limited by small numbers is the first study in adult dengue 
patients looking at ADAMTS 13 levels and its association with dengue severity. In this 
study we looked at several parameters that have been previously associated with dengue 
severity; from demographic variables, clinical features and laboratory findings. Though we 
had only 6 pregnant patients we evaluated the levels of ADAMTS 13 levels in this group of 
patients and compared the same to non-pregnant women with dengue in our cohort. 
       A total of 105 patients were initially selected who had presented to us with an acute 
febrile illness and thrombocytopenia. Amongst these 74 were positive for either NS1 
antigen and/or IgM Dengue. Of these 74 patients, 12 were excluded as mentioned in the 
STROBE diagram, and 62 were included for the analysis. Based on a previous study we had 
assumed a total of 104 patients would be required to achieve an 80% power for this study to 
analyze the association between ADAMTS 13 levels and dengue severity. However in the 
15-month time period we were unable to get enough subjects. As has been mentioned in the 
literature review before, seasonal variations of vector propagation, prior immunological 
background of the community plays an important role in yearly disease incidence and 
severity. 
  In the year 2015, the district of Vellore had seen a surge in dengue cases especially in the 
peri monsoon months. However 2016 had significantly lesser incidence of dengue despite  
heavier rainfall. Early April 2017 onwards there were surges in dengue cases at our centre.  
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We considered the following possibilities for the same: 
1) Significant control measures to curb vector propagation at community levels post the 
2015 dengue epidemic 
2) Potent immunological memory in the community on recent dengue exposure attributing 
also to relatively lesser severity of established cases 
3) In view of lesser severity (as mentioned above), lesser presentation to hospital and 
reporting appearing as lesser disease incidence 
 
Demographic patterns: 
 
    Our study did not show any significant relation of disease severity to age, gender and 
presence of diabetes/hypertension. Multiple prior studies have shown elderly and presence 
of co-morbidities to correlate with dengue severity. However, only a small proportion of our 
patients had comorbidities and that too without any significant organ dysfunction. This 
might undermine the role of the above. The median age of dengue in our study replicates 
most large epidemiological studies. The disease commonly affects young adults and males; 
individuals who spent a considerable amount of time outdoors in our country, leading to 
more contact with vectors and disease incidence (77). No patients had any prior history of 
dengue, malaria or any other mosquito borne arboviral illness. Bigger numbers of study 
subjects can help us in identifying more demographic parameters that can determine 
outcome.  
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Clinical presentation: 
 
    In the absence of laboratory facilities, clinical presentation is the strongest determinant 
in the assessment of dengue severity. Dengue being more often a disease of the tropics and 
developing nations, clinical judgment drives treatment decision and prognostication. Our 
study showed that almost all patients had headache, myalgia and fatiguability, 
manifestations that are common in most viral infections. Other studies from both South and 
Northern India have shown similarly (78–80). However the symptoms are more severe and 
protracted in dengue.  
   The median duration of presentation of subjects in our study was at 5 days after 
symptoms onset. Individual who presented late had mostly been under treatment elsewhere 
and had presented in view of either worsening symptoms or rapidly dropping platelet 
values.  Our centre being a referral tertiary care centre often have patients who come after 
having been diagnosed elsewhere and treatment initiation. This delays their index visit, 
alters symptomatology and laboratory parameters. However our median duration of 5 days 
is early enough given that most dengue fever symptoms start occurring usually towards the 
end of the first week nearing defervescence.  
   A significant proportion of patients had an erythematous blanching rash, characteristic 
of dengue. In our study, the presence of an early rash showed a significant association with 
disease severity. Most bleeding manifestations were minor, while GI bleeding in the form of 
maleana was the most common major bleeding manifestation. Respiratory symptoms were 
present only in a minority of patients, mostly in the form of cough. Cough can be a  
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manifestation of capillary leak in dengue and can predict severity, however our study failed 
to show so. A significant proportion of patient had GI symptoms manifesting as 
nausea/vomiting and loose stools. Both of these contribute to dehydration secondary to poor 
oral intake and increased fluid losses and can push non-severe dengue to more severe forms 
and cause renal dysfunction. Non-specific abdominal pain is also a manifestation of 
capillary leak and can quickly progress to shock. Though these are salient clinical signs of 
severity, in our study they did not show any significant association with severe dengue.  
   Most patients had tachycardia at presentation with the median heart rate being 93/min. 
Median systolic and diastolic blood pressure values were low normal as is expected with 
dengue. A clinical rash was discernable in 88.7% patients with significant odds for severe 
dengue (p=0.002). The presence of any positive respiratory, abdominal or CNS finding did 
not correlate with dengue severity. Severe forms of dengue are usually associated with 
capillary leak and subsequent pleural effusion, free fluid in the abdomen and their 
antecedent symptoms. Possibly the initiation of early resuscitation ameliorated the 
progression of the pathology in these patients and thus these factors did not have a 
significant association in our study with dengue severity. For most patients the majority of 
such symptoms and signs were present at admission, and a very few (6.4%) developed new 
symptoms or findings during their ward stay. Clinical evaluation was done by the principal 
investigator and the attending physician on a daily basis and SOFA scores calculated. 
   We compare in the following table the clinical presentation of sour study subjects with 
other studies from India.  
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Clinical 
parameters 
Laul et al (79) Daniel et al(78) Deshwal et al(80) AVID study 
State/centre Delhi Kerala Uttar Pradesh Tamil Nadu 
Year Jun-Aug 2015 Jun-Dec 2003 Aug-Dec 2013 May16-Aug 17 
Study number 115 250 515 62 
Median age  (yrs) 30  42.6  21-40  22  
M: F (N) 64/51 130/120 376/139 40/22 
Duration of symptoms 
(days) 
Not known 6 Not known 5 
Symptoms: % 
 
Headache 
Myalgia 
Bleeding (any) 
Rash 
Cough 
Breathlessness 
Nausea/vomit 
Abd pain 
Loose stools 
CNS symptoms 
 
 
 
 
100 
86 
21 
21 
- 
19 
68 
57 
27 
2 
 
 
77.2 
- 
15.2 
13.2 
- 
- 
- 
62.4 
15.2 
0.8 
 
 
94.8 
90.7 
5.4 
37.9 
- 
5.2 
5.4 
24.5 
2.5 
1.6 
 
 
100 
100 
23.6 
88.7 
21 
11.3 
53.2 
25.8 
21 
1.6 
 
 
Clinical/radiological 
findings: (%) 
 
Pleural effusion 
Ascites 
 
 
 
 
15 
1 
 
 
 
33 
30 
 
 
 
20 
16.3 
 
 
 
14.5 
11.3 
Dengue severity: (%) 
 
Non severe dengue 
 
Severe dengue 
(includes DHF/DSS) 
 
 
73 
 
27 
 
 
66.4 
 
33.6 
 
 
 
Not mentioned 
 
 
82.2 
 
17.8 
 
Table 11: Comparison of clinical and laboratory parameters in dengue subjects of prior published study 
from India 
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Laboratory parameters: 
 
      Our study looked at multiple laboratory parameters at presentation and subsequent 
stay. Certain parameters that were found significant included the platelet count at 
presentation, lowest platelet counts, highest transaminitis, bilirubin levels at presentation, 
abnormal urinanalysis and presence of any form of kidney injury. On multivariate analysis 
total bilirubin on the day of presentation, and proteinuria were significantly associated with 
dengue severity. The analysis of platelet counts at presentation and lowest platelet counts had 
a confidence interval of 1 on multivariate analysis, rendering it statistically insignificant. 
    Though thrombocytopenia is a disease defining manifestation in dengue the absolute 
values often do not direct correlate with disease severity. Rapidly dropping platelet counts 
have been shown to herald the onset of severe dengue. In this study initial and lowest platelet 
values showed significant association with disease severity on univariate analysis. Though 
the initial platelet value was without any prior transfusion, some patients had been supported 
with platelet rich concentrates post presentation, rendering the lowest platelet counts not a 
thoroughly transfusion unsupported value. 
 
Median 
(Range) 
Non severe dengue Severe forms of 
dengue 
P 
value 
Platelet on day 
of presentation 
(/ cumm) 
58,000 (19000-95000) 27,000 (4,000-93000) 0.008 
Lowest platelet 
counts (/cumm) 
53,000 (6000-78000) 14000 (4000-77000) 0.0001 
 
Table 12: Median platelet values at presentation and lowest platelet values in the two groups of 
dengue patient stratified according to severity and univariate analysis 
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ADAMTS 13: 
 
    Our data failed to show any significant difference in the ADAMTS 13 levels between 
the two groups of dengue patients as described before. The possible explanations include: 
1) Difference in the day of presentation after symptom onset 
2) Lack of biological association 
3) Confounding factors (level of liver dysfunction, acute kidney injury etc.) 
4) Small numbers 
        Further analysis showed a significant association between ADAMTS 13 levels and 
transfusion requirement. Larger studies will be needed to assess gender specific difference, 
variations based on the day of presentation and sample collection and other confounding 
factors to comment on the role and association of ADAMTS 13 in dengue severity.  
 
SOFA score: 
 
           We used SOFA score in our study to assess the disease severity at presentation and 
subsequently for daily follow up. We calculated the highest SOFA score attained by each 
subject. SOFA score has been studied extensively in dengue as has been described before 
(73,74).  In the present study SOFA score on Day 1 and the highest SOFA scores showed 
significant association with dengue severity on univariate analysis, while the SOFA score on 
Day 1 showed significance on multivariate analysis. SOFA can thus be used as a good tool 
for early assessment of disease severity, planning of inpatient versus outpatient care or 
referral in resource poor settings. As mentioned before, the presence of thrombocytopenia as  
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one of its variables, when it is a disease defining manifestation in dengue might overestimate 
risk. The second caveat with SOFA score is the need for monitoring of platelets and bilirubin, 
which is often not possible on a daily basis. Even in our study, while calculating the daily 
SOFA scores the latest laboratory parameters (platelet and bilirubin) were used on those days 
when these tests were not conducted.  
    qSOFA is a point of care clinical tool that has been studied and validated in patients 
with suspected sepsis outside the ICU setting (81). The role of qSOFA in dengue has not 
been adequate looked at. It eliminates the need for laboratory tests and can be used even on 
field settings and emergency wards. However incorporation of dengue specific parameters 
might make it more prudent for its use in assessing dengue severity and large studies will be 
need to establish and validate such a score. As of now SOFA score appears as a valuable tool 
to assess for dengue severity at presentation while W.H.O. dengue severity scales can be used 
for a more dynamic assessment.  
 
Pregnancy and dengue: 
 
   We intended to study the effect of pregnancy on dengue and differences in ADAMTS 
13 levels in pregnant dengue patients compared to non-pregnant women. Our data did not 
show any significant any difference in dengue severity in the pregnant population and also in 
the ADAMTS 13 values. However gestation specific analysis of ADAMTS 13 values might 
throw more light on its levels in pregnancy and role in dengue severity, which could not be 
done in the present study due to small numbers. 
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Study limitations 
 
 Our study had few significant limitations. We were unable to reach the desired number 
of study subjects in view of significant variation in dengue incidence after study initiation. In 
the limited time period we recruited 62 subjects who fulfilled the inclusion criteria. Thus 
several parameters described before which were not statistically significant might actually be 
so when done in large numbers. We had wide confidence intervals of odds ratio (OR) on 
multivariate analysis in view of our small numbers. 
 We had initially conceptualized a serial monitoring of ADAMTS 13 and vWF:CBA 
levels on all patients recruited for the study. However due to logistic and funding issues we 
could perform the above tests only on day 1. A serial monitoring of ADMATS 13 levels 
might provide insight about the ongoing dynamic changes and may help to mirror better the 
thrombocytopenia and disease severity. 
 The number of pregnant subjects in our study was very small which precluded 
significant statistical analysis. Larger numbers of subjects need to be studied to assess the 
differences in ADAMTS 13 levels in this subgroup of patients who usually have a higher 
propensity for severe disease. 
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Conclusion 
 
    The AVID study aimed to look at the role of ADAMTS 13 and its association with 
severity of dengue infection. We also aimed to look at the association of ADAMTS 13 and 
transfusion requirement; the difference in their levels in pregnant women with dengue 
amongst other previously studied parameters. It is the first study in adult dengue patients 
measuring ADAMTS 13 levels and analyzing its association with disease severity. We also 
aimed to analyse SOFA score and its correlation to ADAMTS 13 levels in dengue.  
    In our study low levels of ADAMTS 13 were associated with increased transfusion 
requirement, but not to dengue severity either by W.H.O. grading or by SOFA score. SOFA 
score on Day 1 showed significant association to W.H.O. grading of dengue severity on 
multivariate analysis. We used dichotomous outcome variables by clubbing non severe 
dengue with warning signs and severe dengue into one pool of “more severe dengue” and non 
sever dengue with no warning sign as “less severe dengue.’  
   Though we had only 6 pregnant patients, ADAMTS 13 levels were not significant 
different in them compared to the non-pregnant women. Pregnancy per se did not negatively 
affect dengue severity.  
   Deficiency of ADAMTS 13 is only one of the many mechanisms implicated in 
thrombocytopenia of dengue and its possible role in propagating dengue pathogenesis. Its 
role though appears biologically plausible, needs to be studied in further details to implicate it 
strongly in dengue. Treatment decisions and transfusion practices will change once a causal 
relationship between the two is strongly established. 
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Future direction: 
 Large population and hospital-based studies are warranted to study appropriately the 
variation of ADAMTS 13 levels in dengue and its association with disease severity, level of 
thrombocytopenia and other organ system injury. Factors that can confound ADAMTS 13 
levels like age, blood group, ethnicity should be considered to derive algorithms that 
accurately mimic its role in dengue. Normative data from population should be derived to 
assess trimester-based changes of ADAMTS 13 levels in pregnant women. These should then 
be used to analyse the differences in the levels of ADAMTS 13 in pregnant women with 
dengue and non-pregnant women.  
 As dengue continues to be a global threat and even more so for India, studies aiming to 
find new disease severity markers are important as are scoring systems that can help in early 
disease assessment and modulate treatment decisions.  
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Annexure 2: Patient information sheet 
 
1) What is Dengue?  
Dengue is a common mosquito borne illness that is spread by the bite of Aedes aegypti 
mosquito. The mosquito stays in marshy and water clogged areas and usually bites in the 
daytime.  
2) What are the symptoms of Dengue?  
Dengue presents as an undifferentiated febrile illness, which ranges from only mild fever 
with fatiguability requiring an outpatient basis treatment to a severe illness with multi-organ 
dysfunction requiring hospital admission and organ support.  
Usually dengue presents with high grade fever, a rash over the chest and abdomen, muscle 
pains, headache, eye pain and severe fatiguability. There may be bleeding from the nose or 
oral cavity. Severe forms can present as above with cough, breathlessness, abdominal pain, 
decreased urine output and altered consciousness.  
3) What is ADAMTS 13 and von Willebrand factor collagen activity  
ADAMTS 13 is a protein present in blood, which together with Von Willebrand factor takes 
role in blood coagulation. Blood coagulation is a process by which excessive bleeding is 
prevented in case of any injury to the blood vessels and requires interplay of many proteins, 
blood cells and the blood vessels.  
4) What does this study aim to do?  
The present study aims to find out an association between the levels of the action of the 
above 2 proteins and the severity of Dengue fever  
   
5) In which way will this study affect my treatment at CMC Vellore?  
The study will not affect your treatment in CMC Vellore Hospital in any way. In the event  
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that you wish to participate in the study, your blood samples will be taken at your 
presentation to CMC at the time of your other routine sampling with no additional poke .The 
above sample will be stored and if you test positive for Dengue, these samples will be 
analysed for ADAMTS13 levels and vWF collagen activity. In the event you need admission 
you will be followed up the doctor (principal investigator) in the ward to check your progress. 
Your treatment will not be influenced in this study.  
6) How will this study benefit the treatment of Dengue? The study will help to understand 
the underlying mechanism of disease severity in Dengue fever and also aims to understand 
the reason why platelets decrease in dengue fever. This might help to positively change 
treatment for Dengue fever in the future.  
For any further clarification please feel free to contact the principal investigator at: Dr. 
Jayastu Senapati Email- jsalwayswins@gmail.com  
Mobile number- 07639831089 MD Resident, Department of Medicine, Unit III Christian 
Medical College and Hospital, Vellore.  
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Annexure 3: Patient consent form 
 
AVID Study 
Informed Consent form to participate in a research study  
Study Title: ADAMTS 13 levels and von Willebrand Factor (vWF) collagen activity in 
Dengue fever  
Study Number: ____________  
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________  
Date of Birth / Age: ___________________________  
(Subject)  
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. [ ]   
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [ ]   
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ]   
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a useis only for scientific purpose(s). [ ]   
(v)  I agree to take part in the above study. [ ]   
Signature (or Thumb impression) of the Subject/Legally Acceptable Date: _____/_____/______  
Signatory’s Name: _________________________________ Signature:  
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Or (Thumb sign) 
 
 
 
   
Representative: _________________ Date: _____/_____/______  
Signatory’s Name: _________________________________  
Signature of the Investigator: ________________________ Date: _____/_____/______  
Study Investigator’s Name: _________________________  
Signature or thumb impression of the Witness: ___________________________  
Date: _____/_____/_______  
Name & Address of the Witness: ___________________________  
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Annexure 4: Data abstraction sheet 
 
Clinical proforma for AVID Study 
All patients 
 
Study title: ADAMTS 13 levels and von Willebrand Factor (vWF) collagen 
activity in Dengue fever 
Study number- 
Demographics: 
Name-        Gender- M/F 
Age- 
Address: City-   District-   State- 
Occupation- 1) Professional 2) Skilled   3) Semi skilled 4)Labourer/Unskilled 
: Define- 
Medical past history: 
Comorbidities: 
1) Diabetes- [1] Type 1 [2] Type 2 [3] Pancreatic [4] LADA [5] Drug induced [6]Type not defined 
2) Hypertension- [1] Essential [2] Secondary 
3) Cardiovascular disease- 
[1]Old ACS [2] Diagnosed IHD [3] Congestive cardiac failure [4] Valvular heart disease [5] Others 
4) Cerebrovascular disease- 
[1] Old CVA [2] Old TIA [3] Neurodegenerative disease [4] Others 
5) Chronic kidney disease- [1] On RRT [2] Not on RRT 
6) Endocrinopathy- [1] Thyroid disorders (Hypo/Hyper) [2] Cushing’s [3] Acromegaly [4]Others 
7) Infections- [1] TB [2] Other requiring hospitalization 
If [1]: a) Cured b) On treatment c) Defaulted 
If [1]: a) Pulmonary b) Other  
8) Prior surgery- Y/N 
9) Prior Dengue infection: Y/N: If Y how was it diagnosed- [1] clinical [2] serological [3] unknown 
10) Prior transfusion: Y/N: If Y what was the indication: Define-  
Personal history: 
1) Smoker- Y/N: If Y [1] Present [2] Ex 
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2) Alcohol consumption: Y/N: If Y [1] Dependence pattern [2] Non dependence pattern 
3) Significant family history: Y/N: If Y: Define-  
 
Present Medical History: 
1) Fever: Duration at day of presentation: (Number) 
Temp at presentation- 
2) Rash : Y/N/ Not noticed 
3) Bleeding manifestation: Y/N: If Y- [1] major [2] minor 
(Major- Hematemesis, hemoptysis, hematuria, hematochezia, maleana) 
( Minor- Epistaxis, Oral bleed, Sub conjunctival bleed, skin purpura/petechiae)  
4) Headache: Y/N 
5) Retro-orbital pain: Y/N 
6) Myalgia : Y/N 
7) Fatiguability: Y/N 
8) Respiratory and cardiovascular: 
Cough : Y/N   Breathlessness : Y/N    Chest pain: Y/N     Palpitations : Y/N 
Facial puffiness: Y/N       Pedal edema : Y/N      Subjective decrease in urine output: Y/N 
9) Gastrointestinal: 
Abdominal pain: Y/N     Abdominal distension (subjective) Y/N 
Vomiting: Y/N      Nausea: Y/N     Loose stools: Y/N     Constipation: Y/N    Tensemus: Y/N 
10) Neurological: 
Altered sensorium: Y/N      Seizures: Y/N    Focal deficits: Y/N     
Others: YN: If Y Define- 
11) Outside evaluation and treatment: 
Platelet count:                       Index presentation day from onset of fever: 
Serology: [1] NS1Ag : +/-   [2] Dengue IgM : +/- 
Outside transfusion support: Y/N: If Y: Platelets- ____  Packed cells- _____  FFP- _____  WB- ____ 
 
Clinical Examination: 
At index presentation: 
Casualty/ OPD/ Ward 
1) Pulse-  
Character- [1] Normal volume [2] Bounding [3] Thready 
2) BP- RUL:  
 
3) Respiratory rate:  
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Saturation (room air) – 
 
4) Skin: [1] Blanching rash -Y/N 
    [2] Petechiae - Y/N 
 
5) Bleeding manifestation: [1] Major- Define- 
           [2] Minor- Define- 
 
6) GCS-  /15 
 
7) Respiratory system: 
     Crackles: Y/N: If Y: [1] Basal [2] up to middle 2/3 [3] Diffuse 
     Decreased air entry: Y/N: If Y, define side- R/L/ Both 
     Bronchial breath sounds: Y/N 
     Wheeze: Y/N 
 
8) Abdominal: 
     Tenderness: Y/N: If Y: Guarding: Y/N 
     Free fluid: Y/N 
 
9) CNS examination: 
     In hospital seizure: Y/N 
     Focal deficits: Y/N 
     Other: Y/N: If Y, define-  
 
10) SOFA score at admission:  
       Respiratory: Coagulation:      Liver:         CNS:          Renal:            Cumulative:    
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Investigations:  On day of presentation 
 
1) Hb-       gm/dl 2) WBC-             /cu mm   :- N-      L-      M-     E-     B-     My-    Pro-    BF- 
 
3) Platelet ( Coulter) -                     /cu mm    ( Manual-                     /cu mm) 
 
4) LFT- TB:     DB:     TP:     Alb:     AST:      ALT:      ALP 
 
5) Creatinine:        /mg dl             Urea-       /mg dl 
 
6) Na-  meq   K-  meq 
 
7) PT-           INR-                aPTT-  
 
8) Urinanlysis: 
[1] Bland     [2] hematuria    [3] Pyuria     [4] Both 2 and 3 
 
9) ABG: If done 
pO2-             BE=              Lac= 
 
10) C/S Blood-  
 
11) Dengue serology: [1] NS1Ag +/-    [2]   Dengue  IgM   +/-     [3]   Dengue IgG  +/- 
12) Other serology: Y/N  : If Y, define-  
 
13) Miscellaneous: 
ECG- 
Chest Xray- 
Troponin T-             CKMB-   Malarial Parasites- 
 
USG abdomen- 
14) 
 
Serial monitoring of in patients  
Days  1 2 3 4 5 6 7 8 9 10 
Modality 
SOFA           
Platelet           
PT/INR           
aPTT           
Creat           
AST/ALT           
Organ 
support: 
Ventilation 
Y/N 
If Y 
- [1]NIV/[2] 
INV 
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RRT Y/N 
Transfusion:Y/
N 
If Y 
Platelet= 
FFP= 
Cryo= 
Packed cells= 
          
ADAMTS 13 
 
          
vWF collagen 
activity 
          
 
14) Overall outcome: [1] Discharged cured  [2] died  [3] Discharged against advice   
Duration of stay:  
 
Additional data for pregnant patients 
 
1) Gestational score:  
 
2) Gestational age on day of presentation: 
 
3) Pregnancy complications: Y/N: If Y, [1] PIH  [2] GDM  [3] Pre-ecclampsia/Ecclampisa [4] HELLP 
[5] Prior complicated pregnancies [6] Twin pregnancy  [7] Pregnancy related liver disease [8] Infections 
[9] Artificial conception 
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Annexure 5: Data sheet/ Page 1 
     
                           Name HospNum sex POCare Age State Occupation Diabetes Hypertension CVD CerebroVD CKD PriorTB PriorDengue PriorTrans OtherComorb 
1 HEMANTH KUMAR 527431G 1 2 22 TAMIL NADU STUDENT N N N N N N N N NIL 
2 MD MUSFIKUR RAHMAN BALY 664178G 1 2 44 BANGLADESH BUSINESSMAN N N N N N N N N NIL 
3 RAGHUL M 392696B 1 2 20 TAMIL NADU STUDENT N N N N N N N N NIL 
4 SHAVNIK SINGH 532423G 1 1 20 DELHI/VELLORE STUDENT N N N N N N N N NIL 
5 GOKUL P 541913G 1 2 19 TAMIL NADU STUDENT N N N N N N N N NIL 
6 KOUSHICK T 561970G 1 2 19 TAMIL NADU STUDENT N N N N N N N N NIL 
7 BANU PRIYA 549244G 2 2 32 TAMIL NADU HOUSEWIFE N N N N N N N N NIL 
8 MAHABOOB BEE SHAIKH 548991G 2 2 44 ANDHRA HOUSEWIFE N N N N N N N N NIL 
9 SHUMAILA NOORAIN 634592G 2 2 26 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
10 BANDI SAHITHI 549868G 1 2 18 ANDHRA STUDENT N N N N N N N N NIL 
11 NIKIL B 558555G 1 2 18 ANDHRA STUDENT N N N N N N N N NIL 
12 SHAIK MUNNIJA BEGUM 534760G 2 2 21 ANDHRA HOUSEWIFE N N N N N N N N NIL 
13 PALANI M 541914G 1 2 51 TAMILNADU LABOURER N N N N N N N N NIL 
14 ELUMALAI 548373G 1 2 35 TAMILNADU DRIVER N N N N N N N N NIL 
15 SARASWATI SHARMA 561631G 2 2 25 BIHAR/TAMILNADU HOUSEWIFE N N N N N N N N NIL 
16 SHANTHI 520550G 2 2 48 TAMILNADU STUDENT N N N N N N N N NIL 
17 VIJI 386977B 2 2 21 TAMILNADU STUDENT N N N N N N N N NIL 
18 MEIGNANAM 562934G 1 2 19 TAMILNADU STUDENT N N N N N N N N NIL 
19 LUMINA EVANGELIN 691586D 2 2 29 TAMILNADU NURSE N N N N N N N N NIL 
20 SATHYA D 562476G 2 2 22 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
21 SANTHA KUMAR 564217G 1 2 32 TAMILNADU ARMYMAN N N N N N N N N NIL 
22 SHAMSHUR RAHMAN 564134G 1 2 52 TAMILNADU PROFESSIONAL Y Y N N N N N N NIL 
23 RANJITHA 564287G 2 2 19 TAMILNADU STUDENT N N N N N N N N NIL 
24 CHRISTOPHER RAJASEKHARAN 564572G 1 2 41 TAMILNADU PROFESSIONAL Y Y N N N N N N NIL 
25 PAVITHRA K 566054G 2 2 25 ANDHRA HOUSWEIFE N N N N N N N N NIL 
26 DHEEPAN GSR 863419G 1 2 17 TAMILNADU STUDENT N N N N N N N N NIL 
27 SHANKAR E 566157G 1 2 27 TAMILNADU TECHNICIAN N N N N N N N N NIL 
28 TARUGU PRAVEEN KUMAR 562064G 1 2 26 ANDHRA STUDENT N N N N N N N N NIL 
29 GOPALA KRISHNAN 260624F 1 2 21 TAMILNADU STUDENT N N N N N N N N NIL 
30 ABDUL ROPE G 566473G 1 2 84 TAMILNADU RETIRED N N N N N N N N NIL 
31 PRATIBHA 425949D 2 2 31 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
32 ARUL J 548009G 1 1 25 TAMILNADU LABOURER N N N N N N N N NIL 
33 SANTOSH KUMAR 566973G 1 2 20 ANDHRA STUDENT N N N N N N N N NIL 
34 JOYDEB MONDAL 906170G 1 1 34 WEST BENGAL SHOPKEEPER N N N N N N N N NIL 
35 NASEEMA ALAM 567775G 2 2 25 BIHAR HOUSEWIFE N N N N N N N N NIL 
36 MUTHAMIZH SELVAM 562048G 1 2 42 TAMILNADU MECHANIC Y N N N N N N N NIL 
37 JAI KUMAR Y 567910G 1 2 34 TAMILNADU TEACHER N N N N N N N N NIL 
38 TANVEER AHAMED 986810F 1 2 26 TAMILNADU BUSINESS N N N N N N N N NIL 
39 NAVEEN KUMAR 930245G 1 1 27 TAMILNADU LABOURER N N N N N N N N NIL 
40 RAJASEKAR P 078186G 1 2 54 TAMILNADU SERVICEMAN Y N N N N N N N NIL 
41 JAYALAKSHMI 930290G 2 2 41 TANILNADU HOUSEWIFE N N N N N N N N NIL 
42 ESWARAMMA 942742G 2 2 42 ANDHRA HOUSEWIFE N N N N N N N N NIL 
43 AASIMA TABASSUM 930413G 2 2 30 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
44 PALANISAMY K 930548G 1 2 38 TAMILNADU CLERK N N N N N N N N NIL 
45 PUNNET KUMAR REDDY 930694G 1 2 16 ANDHRA STUDENT N N N N N N N N NIL 
46 JASON JOHN DEVARAJ 930656G 1 2 20 KARNATAKA STUDENT N N N N N N N N NIL 
47 RAJA RAJAN 930680G 1 2 32 TAMILNADU LABOURER N N N N N N N N NIL 
48 VIJAY RAGHAVAN 930745G 1 2 30 TAMILNADU BUSINESS N N N N N N N N NIL 
49 SANGEETHA LAKSHMI 930579G 2 2 35 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
50 MOHAMMED ARAFATH 930746G 1 2 21 TAMILNADU STUDENT N N N N N N N N NIL 
51 SHEELA 930835G 2 2 35 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
52 CHRISTY P 545766G 2 2 26 TAMILNADU DOCTOR N N N N N N N N NIL 
53 NAVIYARASAN 931111G 2 1 18 TAMILNADU STUDENT N N N N N N N N NIL 
54 SHANKAR K 931126G 1 1 23 TAMILNADU LABOURER N N N N N N N N NIL 
55 SIKANDER BARWA 954571G 1 1 28 JHARKHAND SERVICEMAN N N N N N N N N NIL 
56 SATHYARAJ 931864G 1 1 29 TAMILNADU BUSINESSMAN N N N N N N N N NIL 
57 MOHAMMAD RAFI 867152G 1 2 21 TAMILNADU STUDENT N N N N N N N N NIL 
58 VENKATESAN 932811G 1 2 37 TAMILNADU BUSINESSMAN N N N N N N N N NIL 
59 DHANIYA SAJIDA 577983G 2 2 40 TAMILNADU HOUSEWIFE N N N N N N N N NIL 
60 MURUGAN A 933263G 1 2 28 KARNATAKA SERVICEMAN N Y N N N N N N NIL 
61 ZEENATH BEGUM 933282G 2 2 19 TAMILNADU STUDENT N N N N N N N N NIL 
62 Y SUNDAR REDDY 933278G 1 2 28 ANDHRA PROFESSIONAL N N N N N N N N NIL 
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Data sheet/ Page 2 
	 Diabetes	 Hypertension	 CVD	 CerebroVD	 CKD	 PriorTB	 PriorDengue	 PriorTrans	 OtherComorb	
1	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
2	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
3	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
4	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
5	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
6	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
7	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
8	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
9	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
10	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
11	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
12	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
13	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
14	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
15	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
16	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
17	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
18	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
19	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
20	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
21	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
22	 Y	 Y	 N	 N	 N	 N	 N	 N	 NIL	
23	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
24	 Y	 Y	 N	 N	 N	 N	 N	 N	 NIL	
25	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
26	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
27	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
28	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
29	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
30	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
31	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
32	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
33	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
34	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
35	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
36	 Y	 N	 N	 N	 N	 N	 N	 N	 NIL	
37	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
38	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
39	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
40	 Y	 N	 N	 N	 N	 N	 N	 N	 NIL	
41	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
42	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
43	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
44	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
45	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
46	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
47	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
48	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
49	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
50	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
51	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
52	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
53	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
54	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
55	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
56	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
57	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
58	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
59	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
60	 N	 Y	 N	 N	 N	 N	 N	 N	 NIL	
61	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
62	 N	 N	 N	 N	 N	 N	 N	 N	 NIL	
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Data sheet/ Page 3 
	 Smoker	 Alcohol	 DOP	 Temp	 Rash	 Bleeding	 Headache	 Myalgia	 Fatiguability	 Cough	
1	 N	 N	 7	 98	 Y	 1	 Y	 Y	 Y	 N	
2	 N	 N	 5	 101	 Y	 1	 Y	 Y	 Y	 N	
3	 N	 N	 6	 101	 Y	 1	 Y	 Y	 Y	 N	
4	 N	 N	 4	 100	 Y	 1	 Y	 Y	 Y	 N	
5	 N	 N	 6	 98	 Y	 1	 Y	 Y	 Y	 N	
6	 N	 N	 4	 100.8	 N	 1	 Y	 Y	 Y	 N	
7	 N	 N	 4	 101	 Y	 1	 Y	 Y	 Y	 Y	
8	 N	 N	 10	 102	 Y	 3	 Y	 Y	 Y	 N	
9	 N	 N	 4	 100	 Y	 1	 Y	 Y	 Y	 Y	
10	 N	 N	 5	 98	 Y	 2	 Y	 Y	 Y	 N	
11	 N	 N	 4	 100	 Y	 1	 Y	 Y	 Y	 N	
12	 N	 N	 7	 100	 Y	 1	 Y	 Y	 Y	 N	
13	 Y	 N	 10	 101	 Y	 1	 Y	 Y	 Y	 Y	
14	 N	 N	 6	 101	 Y	 1	 Y	 Y	 Y	 N	
15	 N	 N	 7	 100	 N	 1	 Y	 Y	 Y	 N	
16	 N	 N	 10	 98	 N	 1	 Y	 Y	 Y	 N	
17	 N	 N	 6	 98	 N	 1	 N	 Y	 Y	 N	
18	 N	 N	 7	 98	 Y	 2	 Y	 Y	 Y	 N	
19	 N	 N	 5	 98	 N	 1	 N	 Y	 Y	 N	
20	 N	 N	 3	 101	 Y	 1	 Y	 Y	 Y	 N	
21	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
22	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
23	 N	 N	 14	 98	 Y	 1	 Y	 Y	 Y	 N	
24	 N	 N	 3	 100	 N	 1	 Y	 Y	 Y	 N	
25	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
26	 N	 N	 4	 100	 Y	 1	 Y	 Y	 Y	 N	
27	 N	 N	 6	 98	 Y	 1	 Y	 Y	 Y	 Y	
28	 N	 N	 15	 100.2	 Y	 3	 Y	 Y	 Y	 Y	
29	 N	 N	 4	 100.6	 Y	 2	 Y	 Y	 Y	 Y	
30	 N	 N	 7	 98	 Y	 3	 Y	 Y	 Y	 Y	
31	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
32	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
33	 N	 N	 5	 100	 N	 1	 Y	 Y	 Y	 N	
34	 N	 N	 4	 99.8	 N	 1	 Y	 Y	 Y	 N	
35	 N	 N	 9	 98	 Y	 2	 Y	 Y	 Y	 N	
36	 N	 N	 5	 98	 Y	 3	 Y	 Y	 Y	 N	
37	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
38	 N	 N	 3	 101	 Y	 1	 Y	 Y	 Y	 N	
39	 N	 N	 7	 100	 Y	 2	 Y	 Y	 Y	 Y	
40	 N	 N	 3	 102	 Y	 1	 Y	 Y	 Y	 N	
41	 N	 N	 5	 100	 Y	 1	 Y	 Y	 Y	 N	
42	 N	 N	 7	 100	 Y	 1	 Y	 Y	 Y	 N	
43	 N	 N	 5	 98	 Y	 2	 Y	 Y	 Y	 N	
44	 N	 N	 6	 98	 Y	 1	 Y	 Y	 Y	 N	
45	 N	 N	 4	 98	 Y	 2	 Y	 Y	 Y	 N	
46	 N	 N	 5	 100	 Y	 1	 Y	 Y	 Y	 N	
47	 N	 N	 4	 98	 Y	 1	 Y	 Y	 Y	 N	
48	 N	 N	 5	 98	 Y	 3	 Y	 Y	 Y	 N	
49	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
50	 N	 N	 6	 98	 Y	 1	 Y	 Y	 Y	 Y	
51	 N	 N	 5	 100.4	 Y	 1	 Y	 Y	 Y	 N	
52	 N	 N	 2	 101	 Y	 1	 Y	 Y	 Y	 Y	
53	 N	 N	 4	 100	 Y	 1	 Y	 Y	 Y	 N	
54	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 N	
55	 N	 N	 4	 100	 Y	 1	 Y	 Y	 Y	 N	
56	 N	 N	 6	 98	 Y	 1	 Y	 Y	 Y	 N	
57	 N	 N	 7	 98	 Y	 1	 Y	 Y	 Y	 N	
58	 N	 N	 7	 98	 Y	 3	 Y	 Y	 Y	 Y	
59	 N	 N	 5	 98	 Y	 1	 Y	 Y	 Y	 Y	
60	 N	 N	 5	 101	 Y	 2	 Y	 Y	 Y	 Y	
61	 N	 N	 4	 98	 Y	 1	 Y	 Y	 Y	 N	
62	 N	 N	 3	 101	 Y	 1	 Y	 Y	 Y	 N	
 
 
	 107	
 
Data sheet/ Page 4 
 
	 Breathlessness	 ChestPain	 DecreaseUO	 AbdPain	 NauseaVomit	 LooseStools	 AltSens	 Seizures	
1	 N	 N	 N	 N	 N	 N	 N	 N	
2	 N	 N	 N	 N	 N	 N	 N	 N	
3	 N	 N	 N	 N	 Y	 N	 N	 N	
4	 N	 N	 N	 N	 N	 N	 N	 N	
5	 N	 N	 N	 N	 Y	 N	 N	 N	
6	 N	 N	 N	 N	 Y	 N	 N	 N	
7	 Y	 N	 N	 N	 Y	 N	 N	 N	
8	 Y	 N	 N	 Y	 Y	 N	 N	 N	
9	 N	 N	 N	 N	 N	 N	 N	 N	
10	 N	 N	 N	 N	 Y	 N	 N	 N	
11	 N	 N	 N	 N	 N	 N	 N	 N	
12	 N	 N	 N	 N	 N	 N	 N	 N	
13	 N	 N	 N	 N	 Y	 N	 N	 N	
14	 N	 N	 N	 N	 N	 N	 N	 N	
15	 N	 N	 N	 N	 N	 N	 N	 N	
16	 N	 N	 N	 N	 Y	 N	 N	 N	
17	 N	 N	 N	 N	 N	 Y	 N	 N	
18	 N	 N	 N	 N	 Y	 N	 N	 N	
19	 N	 N	 N	 N	 Y	 Y	 N	 N	
20	 N	 N	 N	 N	 N	 N	 N	 N	
21	 N	 N	 N	 N	 Y	 N	 N	 N	
22	 N	 N	 N	 N	 N	 N	 N	 N	
23	 Y	 N	 N	 N	 N	 N	 Y	 N	
24	 N	 N	 N	 N	 Y	 N	 N	 N	
25	 N	 N	 N	 Y	 Y	 N	 N	 N	
26	 N	 N	 N	 N	 N	 N	 N	 N	
27	 N	 N	 N	 Y	 Y	 N	 N	 N	
28	 Y	 N	 N	 Y	 Y	 Y	 N	 N	
29	 Y	 N	 N	 N	 N	 N	 N	 N	
30	 N	 N	 N	 N	 N	 Y	 N	 N	
31	 N	 N	 N	 N	 Y	 N	 N	 N	
32	 N	 N	 N	 N	 N	 N	 N	 N	
33	 N	 N	 N	 N	 Y	 N	 N	 N	
34	 N	 N	 N	 N	 N	 N	 N	 N	
35	 N	 N	 N	 Y	 Y	 N	 N	 N	
36	 N	 N	 N	 N	 N	 N	 N	 N	
37	 N	 N	 N	 N	 N	 N	 N	 N	
38	 N	 N	 N	 Y	 Y	 Y	 N	 N	
39	 N	 N	 N	 N	 N	 N	 N	 N	
40	 N	 N	 N	 N	 N	 N	 N	 N	
41	 N	 N	 N	 N	 N	 N	 N	 N	
42	 N	 N	 N	 Y	 Y	 Y	 N	 N	
43	 N	 N	 N	 Y	 N	 N	 N	 N	
44	 N	 N	 N	 N	 N	 N	 N	 N	
45	 N	 N	 N	 Y	 Y	 Y	 N	 N	
46	 N	 N	 N	 N	 Y	 Y	 N	 N	
47	 N	 N	 N	 N	 N	 N	 N	 N	
48	 N	 N	 N	 N	 N	 Y	 N	 N	
49	 N	 N	 N	 Y	 Y	 N	 N	 N	
50	 N	 N	 N	 N	 N	 N	 N	 N	
51	 N	 N	 N	 Y	 Y	 N	 N	 N	
52	 N	 Y	 N	 Y	 N	 N	 N	 N	
53	 N	 N	 N	 N	 Y	 N	 N	 N	
54	 N	 N	 N	 N	 Y	 N	 N	 N	
55	 N	 N	 N	 N	 Y	 N	 N	 N	
56	 N	 N	 N	 N	 N	 N	 N	 N	
57	 N	 N	 N	 Y	 Y	 N	 N	 N	
58	 Y	 N	 N	 Y	 Y	 Y	 N	 N	
59	 N	 N	 N	 N	 Y	 Y	 N	 N	
60	 Y	 N	 N	 Y	 Y	 Y	 N	 N	
61	 N	 N	 N	 N	 Y	 N	 N	 N	
62	 N	 N	 N	 Y	 Y	 Y	 N	 N	
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Data sheet/ Page 5 
	 Misc	 Pulse	 PulseCharacter	 SBP	 DBP	 RR	 SPO2	 Blanchingrash	 Petechiae	
1	 NIL	 88	 1	 90	 60	 20	 99	 Y	 N	
2	 NIL	 80	 1	 110	 80	 20	 98	 Y	 N	
3	 NIL	 128	 1	 90	 60	 20	 98	 Y	 N	
4	 NIL	 110	 1	 100	 70	 20	 100	 Y	 N	
5	 NIL	 80	 1	 110	 70	 18	 98	 Y	 Y	
6	 NIL	 120	 1	 100	 60	 22	 99	 N	 N	
7	 NIL	 110	 2	 100	 60	 26	 93	 Y	 N	
8	 NIL	 126	 1	 110	 60	 40	 88	 Y	 N	
9	 PREGNANT	 98	 1	 100	 60	 18	 98	 Y	 N	
10	 NIL	 100	 1	 120	 80	 34	 97	 Y	 N	
11	 NIL	 95	 1	 110	 60	 20	 99	 Y	 N	
12	 PREGNANT	 130	 1	 90	 60	 26	 98	 Y	 N	
13	 NIL	 110	 1	 90	 60	 18	 99	 Y	 N	
14	 NIL	 80	 1	 90	 60	 18	 94	 Y	 N	
15	 PREGNANT	 96	 1	 100	 60	 18	 100	 N	 N	
16	 NIL	 112	 1	 100	 60	 30	 96	 N	 N	
17	 NIL	 90	 1	 110	 60	 18	 100	 N	 N	
18	 NIL	 68	 2	 110	 70	 14	 97	 Y	 N	
19	 NIL	 88	 1	 130	 70	 16	 98	 N	 N	
20	 NIL	 100	 1	 100	 60	 18	 99	 Y	 N	
21	 NIL	 120	 1	 100	 60	 16	 99	 Y	 N	
22	 NIL	 94	 1	 110	 70	 18	 98	 Y	 N	
23	 NIL	 119	 2	 94	 60	 34	 90	 Y	 N	
24	 NIL	 84	 1	 120	 80	 20	 99	 N	 N	
25	 NIL	 96	 1	 90	 60	 18	 99	 Y	 N	
26	 NIL	 90	 1	 110	 60	 20	 100	 Y	 N	
27	 NIL	 100	 1	 120	 70	 24	 97	 Y	 N	
28	 NIL	 102	 1	 120	 70	 26	 96	 Y	 N	
29	 NIL	 110	 1	 110	 90	 20	 96	 Y	 N	
30	 NIL	 92	 1	 120	 60	 24	 96	 Y	 N	
31	 NIL	 80	 1	 100	 90	 16	 99	 Y	 N	
32	 NIL	 94	 1	 100	 70	 20	 99	 Y	 N	
33	 NIL	 84	 1	 120	 80	 22	 99	 Y	 N	
34	 NIL	 100	 1	 130	 70	 20	 100	 N	 N	
35	 PREGNANT	 76	 1	 110	 70	 16	 97	 Y	 N	
36	 NIL	 80	 1	 110	 70	 19	 99	 Y	 N	
37	 NIL	 92	 1	 100	 60	 22	 100	 Y	 N	
38	 NIL	 98	 1	 100	 60	 20	 98	 Y	 N	
39	 NIL	 84	 1	 100	 60	 22	 98	 Y	 N	
40	 NIL	 106	 2	 90	 50	 22	 99	 Y	 N	
41	 NIL	 80	 1	 100	 60	 16	 99	 Y	 N	
42	 NIL	 84	 1	 90	 60	 22	 99	 Y	 N	
43	 PREGNANT	 88	 1	 110	 70	 18	 98	 Y	 N	
44	 NIL	 76	 1	 110	 80	 14	 100	 Y	 N	
45	 NIL	 72	 1	 100	 60	 20	 97	 Y	 N	
46	 NIL	 120	 1	 100	 70	 20	 98	 Y	 N	
47	 NIL	 88	 1	 100	 70	 16	 100	 Y	 N	
48	 NIL	 90	 1	 110	 70	 24	 99	 Y	 N	
49	 NIL	 126	 1	 120	 90	 22	 98	 Y	 N	
50	 NIL	 76	 1	 100	 60	 16	 99	 Y	 N	
51	 NIL	 84	 1	 70	 50	 22	 96	 Y	 N	
52	 PREGNANT	 100	 1	 100	 60	 20	 97	 Y	 N	
53	 NIL	 100	 1	 100	 60	 20	 99	 Y	 N	
54	 NIL	 84	 1	 110	 70	 20	 100	 Y	 N	
55	 NIL	 80	 1	 110	 60	 22	 100	 Y	 N	
56	 NIL	 90	 1	 120	 70	 22	 98	 Y	 N	
57	 NIL	 100	 1	 110	 60	 20	 98	 Y	 N	
58	 NIL	 120	 1	 110	 60	 24	 98	 Y	 Y	
59	 NIL	 68	 1	 100	 70	 21	 98	 Y	 N	
60	 NIL	 112	 1	 120	 70	 24	 98	 Y	 N	
61	 NIL	 92	 1	 100	 70	 22	 100	 Y	 N	
62	 NIL	 90	 1	 100	 70	 24	 99	 Y	 N	
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Data sheet/ Page 6	 	 	 	 	 	 	 	 	
 
	 	 GCS	 AbdNormal	 AbdFreefluid	 AbdGuarding	 AbdTender	 RespNormal	 RSredairentry	 RSBBS	
1	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
2	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
3	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
4	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
5	 	 15	 N	 Y	 N	 Y	 Y	 N	 N	
6	 	 15	 N	 N	 N	 Y	 Y	 N	 N	
7	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
8	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
9	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
10	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
11	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
12	 	 15	 N	 N	 N	 Y	 Y	 N	 N	
13	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
14	 	 15	 N	 N	 N	 Y	 Y	 N	 N	
15	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
16	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
17	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
18	 	 15	 N	 Y	 N	 Y	 N	 Y	 N	
19	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
20	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
21	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
22	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
23	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
24	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
25	 	 15	 N	 N	 N	 Y	 Y	 N	 N	
26	 	 15	 Y	 N	 N	 N	 N	 Y	 N	
27	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
28	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
29	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
30	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
31	 	 15	 Y	 N	 N	 N	 Y	 N	
	32	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
33	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
34	 	 15	 Y	 N	 N	 N	 Y	 N	
	35	 	 15	 N	 Y	 N	 Y	 N	 Y	 N	
36	 	 15	 N	 Y	 N	 Y	 N	 Y	 N	
37	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
38	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
39	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
40	 	 15	 Y	 N	 N	 N	 N	 Y	 N	
41	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
42	 	 15	 Y	 N	 N	 N	 N	 Y	 N	
43	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
44	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
45	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
46	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
47	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
48	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
49	 	 15	 N	 Y	 N	 N	 N	 Y	 N	
50	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
51	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
52	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
53	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
54	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
55	 	 15	 N	 Y	 Y	 Y	 N	 Y	 N	
56	 	 15	 N	 Y	 N	 N	 N	 Y	 N	
57	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
58	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
59	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
60	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
61	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
62	 	 15	 Y	 N	 N	 N	 Y	 N	 N	
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Data sheet/ Page 7 
     	
	
	
RSCrackles	 RSWheeze	 RScondsounds	 CNSNormal	 CNSAltSens	 CNSSeizures	
             
1	 N	 N	 N	 Y	 N	 N	
2	 N	 N	 N	 Y	 N	 N	
3	 N	 N	 N	 Y	 N	 N	
4	 N	 N	 N	 Y	 N	 N	
5	 N	 N	 N	 Y	 N	 N	
6	 N	 N	 N	 Y	 N	 N	
7	 N	 N	 N	 Y	 N	 N	
8	 N	 N	 N	 Y	 N	 N	
9	 N	 N	 N	 Y	 N	 N	
10	 N	 N	 N	 Y	 N	 N	
11	 N	 N	 N	 Y	 N	 N	
12	 N	 N	 N	 Y	 N	 N	
13	 N	 N	 N	 Y	 N	 N	
14	 N	 N	 N	 Y	 N	 N	
15	 N	 N	 N	 Y	 N	 N	
16	 N	 N	 N	 Y	 N	 N	
17	 N	 N	 N	 Y	 N	 N	
18	 N	 N	 N	 Y	 N	 N	
19	 N	 N	 N	 Y	 N	 N	
20	 N	 N	 N	 Y	 N	 N	
21	 N	 N	 N	 Y	 N	 N	
22	 N	 N	 N	 Y	 N	 N	
23	 N	 N	 N	 Y	 N	 N	
24	 N	 N	 N	 Y	 N	 N	
25	 N	 N	 N	 Y	 N	 N	
26	 N	 N	 N	 Y	 N	 N	
27	 N	 N	 N	 Y	 N	 N	
28	 N	 N	 N	 Y	 N	 N	
29	 N	 N	 N	 Y	 N	 N	
30	 N	 N	 N	 Y	 N	 N	
31	 N	 N	 N	 Y	 N	 N	
32	 N	 N	 N	 Y	 N	 N	
33	 N	 N	 N	 Y	 N	 N	
34	 N	 N	 N	 Y	 N	 N	
35	 Y	 N	 Y	 Y	 N	 N	
36	 N	 N	 N	 Y	 N	 N	
37	 N	 N	 N	 Y	 N	 N	
38	 N	 N	 N	 Y	 N	 N	
39	 N	 N	 N	 Y	 N	 N	
40	 Y	 N	 N	 N	 Y	 N	
41	 N	 N	 N	 Y	 N	 N	
42	 N	 N	 N	 Y	 N	 N	
43	 N	 N	 N	 Y	 N	 N	
44	 N	 N	 N	 Y	 N	 N	
45	 N	 N	 N	 Y	 N	 N	
46	 N	 N	 N	 Y	 N	 N	
47	 N	 N	 N	 Y	 N	 N	
48	 N	 N	 N	 Y	 N	 N	
49	 N	 N	 N	 Y	 N	 N	
50	 N	 N	 N	 Y	 N	 N	
51	 N	 N	 N	 Y	 N	 N	
52	 N	 N	 N	 Y	 N	 N	
53	 N	 N	 N	 Y	 N	 N	
54	 N	 N	 N	 Y	 N	 N	
55	 N	 N	 N	 Y	 N	 N	
56	 N	 N	 Y	 Y	 N	 N	
57	 N	 N	 N	 Y	 N	 N	
58	 N	 N	 N	 Y	 N	 N	
59	 N	 N	 N	 Y	 N	 N	
60	 N	 N	 N	 Y	 N	 N	
61	 N	 N	 N	 Y	 N	 N	
62	 N	 N	 N	 Y	 N	 N	
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Data sheet/ Page 8 
 
 
	 SOFARespi	 SOFACoag	 SOFALiver	 SOFACVS	 SOFACNS	 SOFARenal	 SOFADay1	 PlateletCoulter	
1	 0	 3	 0	 0	 0	 1	 4	 33000	
2	 0	 3	 0	 0	 0	 0	 3	 20000	
3	 0	 2	 0	 0	 0	 0	 2	 67000	
4	 0	 2	 0	 0	 0	 0	 2	 50000	
5	 0	 3	 0	 0	 0	 0	 3	 42000	
6	 0	 3	 0	 0	 0	 0	 3	 21000	
7	 0	 2	 0	 0	 0	 0	 2	 51000	
8	 0	 2	 0	 0	 0	 0	 2	 72000	
9	 0	 2	 0	 0	 0	 0	 2	 78000	
10	 0	 2	 1	 0	 0	 0	 3	 55000	
11	 0	 3	 0	 0	 0	 0	 3	 23000	
12	 0	 4	 0	 1	 0	 0	 5	 11000	
13	 0	 2	 0	 0	 0	 0	 2	 58000	
14	 0	 2	 0	 0	 0	 0	 2	 76000	
15	 0	 2	 0	 0	 0	 0	 2	 66000	
16	 0	 4	 0	 0	 0	 0	 4	 18000	
17	 0	 3	 0	 0	 0	 2	 5	 40000	
18	 0	 3	 0	 0	 0	 0	 3	 29000	
19	 0	 4	 0	 0	 0	 0	 4	 12000	
20	 0	 2	 0	 0	 0	 0	 2	 69000	
21	 0	 4	 0	 0	 0	 0	 4	 8000	
22	 0	 3	 0	 0	 0	 0	 3	 35000	
23	 0	 2	 0	 1	 0	 1	 4	 77000	
24	 0	 3	 0	 0	 0	 0	 3	 30000	
25	 0	 2	 0	 1	 0	 0	 3	 53000	
26	 0	 2	 0	 0	 0	 0	 2	 57000	
27	 0	 3	 0	 0	 0	 0	 3	 22000	
28	 0	 3	 0	 0	 0	 0	 3	 29000	
29	 0	 2	 0	 0	 0	 0	 2	 53000	
30	 0	 3	 0	 0	 0	 0	 3	 25000	
31	 0	 3	 0	 0	 0	 0	 3	 31000	
32	 0	 4	 0	 0	 0	 1	 5	 12000	
33	 0	 4	 2	 0	 0	 1	 7	 16000	
34	 1	 3	 1	 0	 0	 1	 6	 27000	
35	 1	 4	 2	 0	 0	 1	 8	 14000	
36	 0	 4	 0	 0	 0	 0	 4	 14000	
37	 0	 3	 0	 0	 0	 0	 3	 20000	
38	 0	 4	 0	 0	 0	 0	 4	 11000	
39	 0	 2	 1	 0	 0	 1	 4	 54000	
40	 1	 3	 3	 0	 0	 1	 8	 47000	
41	 0	 4	 0	 0	 0	 1	 5	 15000	
42	 0	 4	 0	 0	 0	 0	 4	 12000	
43	 0	 2	 0	 0	 0	 0	 2	 58000	
44	 0	 2	 0	 0	 0	 0	 2	 71000	
45	 0	 4	 0	 0	 0	 0	 4	 19000	
46	 0	 2	 0	 0	 0	 0	 2	 58000	
47	 1	 4	 0	 0	 0	 1	 6	 17000	
48	 0	 2	 0	 0	 0	 0	 2	 55000	
49	 1	 2	 0	 0	 0	 1	 4	 93000	
50	 0	 4	 0	 0	 0	 0	 4	 4000	
51	 0	 4	 0	 0	 0	 0	 4	 19000	
52	 0	 4	 0	 0	 0	 0	 4	 19000	
53	 0	 4	 2	 0	 0	 0	 6	 14000	
54	 0	 2	 0	 0	 0	 0	 2	 65000	
55	 3	 2	 0	 0	 0	 0	 5	 75000	
56	 1	 4	 0	 0	 0	 0	 5	 17000	
57	 0	 1	 0	 0	 0	 0	 2	 95000	
58	 0	 4	 1	 0	 0	 0	 5	 16000	
59	 0	 3	 0	 0	 0	 0	 3	 41000	
60	 0	 3	 0	 0	 0	 0	 3	 43000	
61	 0	 4	 0	 0	 0	 0	 4	 15000	
62	 0	 3	 0	 0	 0	 0	 3	 31000	
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 Hb TWBC Neutrophil Lymph Monocyte Creat Urea Sodium Potassium Bicarb 
 
1 16.8 4700 72 20 6 1.3 21 132 4 16 
2 13.2 2700 26 64 10 0.63 15 139 3.8 17 
3 14.1 2200 70 24 6 1 
 
136 3.9 14 
4 10.4 6100 91 4 5 1.08 15 132 3 24 
5 16 9800 44 48 6 0.87 18 137 3.3 20 
6 17.3 3800 56 34 10 0.89 12 138 4.3 21 
7 19.2 3400 65 23 8 0.87 13 130 3.8 23 
8 13.6 2900 66 20 9 0.79 25 135 4.1 24 
9 14.1 2000 49 29 19 0.7 17 140 4.2 24 
10 17.3 3400 46 38 8 1.03 36 127 3.8 20 
11 11 1800 80 12 4 0.47 
 
133 3.6 
 12 15.5 4400 60 30 10 1.02 21 136 3.8 21 
13 14.2 8200 44 46 10 0.71 12 134 3.9 22 
14 9.7 3300 63 27 10 0.63 25 130 3.6 14 
15 13.3 3100 85 10 5 0.93 20 135 4.1 23 
16 17 6300 61 18 21 1.11 19 133 4.2 19 
17 14.9 4700 71 19 8 2.18 35 133 3.5 24 
18 14.4 3300 65 28 5 0.99 15 129 4.4 18 
19 14.6 3100 60 25 15 0.94 11 133 4.7 
 20 8.7 4500 70 20 8 0.46 8 128 3.1 22 
21 13.7 9900 28 55 15 0.67 21 138 4 16 
22 12.1 1700 60 24 16 0.68 13 134 2.8 19 
23 14.5 2600 50 26 24 1.59 70 130 3.7 17 
24 17.6 4500 50 30 8 0.94 
 
135 4.1 15 
25 16.1 2900 68 22 10 1.1 30 135 3.8 19 
26 5.2 3300 79 14 7 1.06 16 131 3.7 18 
27 14.6 3200 60 26 14 0.83 20 132 3.6 
 28 10.6 5100 84 11 5 0.52 13 132 3.7 14 
29 14.5 15000 48 50 2 0.92 20 135 3.6 
 30 15.8 6500 50 33 14 1.07 19 133 3.6 19 
31 17 3300 71 26 3 1.16 15 136 4.1 
 32 19 6500 92 2 2 1.33 
 
129 5.7 15 
33 10.1 10300 83 5 9 1.21 65 134 3.2 15 
34 19.2 3400 78 13 8 1.44 50 135 3.6 15 
35 16.7 13700 68 15 7 1.35 71 128 4.4 14 
36 13.4 5400 48 37 13 0.72 
 
135 3.6 22 
37 14 1700 72 24 4 0.62 
 
135 3.3 23 
38 16 5000 38 40 22 0.86 16 134 4.3 19 
39 16.1 4900 52 30 18 1.28 25 134 3.7 13 
40 10.8 37600 73 5 3 1.7 136 125 4.2 6 
41 14.8 4500 42 42 15 1.36 36 132 4.5 
 42 17.3 4100 37 38 21 0.85 10 130 4 17 
43 10.9 2300 64 26 8 0.5 10 130 3.3 19 
44 12.2 3300 59 33 8 0.53 
 
136 3.5 17 
45 10.9 4300 48 24 18 0.58 
 
135 3.6 20 
46 11.4 3000 23 64 4 0.64 
 
134 3.5 23 
47 17.2 7400 74 19 4 1.94 64 139 4.5 12 
48 11.4 2400 48 27 24 0.51 11 132 3 
 49 15.7 4000 76 17 17 1.21 27 138 4.2 
 50 13.5 9000 89 8 3 1.09 62 125 3.7 
 51 15.6 7900 61 24 12 0.47 12 136 3.4 
 52 16.1 2900 59 33 8 1.19 24 135 3.7 
 53 11.6 3800 43 40 17 0.46 18 141 3.8 
 54 13.4 5200 52 3 11 0.59 
 
132 3.9 
 55 3.5 29800 78 9 2 0.96 
 
142 4.3 
 56 13.4 6700 36 53 11 0.67 15 136 3.9 
 57 14.3 3100 66 24 10 0.89 
 
138 3.7 
 58 16.8 6800 30 24 29 0.82 34 134 3.8 
 59 15.4 3300 79 16 5 0.97 15 134 4.6 
 60 13.5 4500 67 18 15 1 
 
136 3.5 
 61 16.8 9400 42 49 9 0.82 
 
132 3.5 
 62 17.2 4800 50 41 9 0.75 14 135 4.5 
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 DirectBil TotalProt Albumin SGOT SGPT ALP PT INR aPTT Urinanlysis Hematuria 
 
1 0.2 7.7 4.7 1372 508 79 
   
Y N 
2 0.1 6.9 4 515 430 38 10.1 0.93 32.8 Y N 
3 0.2 7.3 3.6 129 60 49 
   
Y N 
4 0.3 7 4.5 23 12 52 
   
N N 
5 0.4 6.8 3.5 446 271 51 10.3 0.95 33.6 Y N 
6 0.2 6.2 3.2 228 149 70 
   
Y N 
7 0.7 7.4 3.9 1480 605 72 10.3 0.95 26.5 Y N 
8 0.1 7.4 4.4 47 37 51 9.4 0.86 32.8 Y N 
9 0.2 6.9 4.2 54 45 83 
   
N N 
10 0.4 7.9 4.3 126 52 71 
   
N N 
11 0.1 5.5 3.4 118 59 112 9.4 0.87 73.4 Y N 
12 0.1 6.6 3.4 70 31 74 8.9 0.82 48 Y N 
13 0.2 8.3 4 56 34 34 9.7 0.9 33.1 N N 
14 0.3 7.3 4.2 165 123 68 
   
Y N 
15 0.9 6.6 3.8 514 363 82 
   
Y Y 
16 0.3 7 4 123 81 107 
   
N N 
17 0.2 7.5 4.6 385 219 75 
   
Y N 
18 0.4 6.7 3.6 1119 428 187 11.5 1.05 56.4 Y N 
19 0.3 6.7 3.9 59 36 50 
   
Y N 
20 0.3 6.7 3.3 214 74 69 
   
Y N 
21 0.5 6.4 3.2 168 127 361 
   
Y N 
22 0.4 6.1 3.3 871 253 67 
   
N N 
23 0.1 6.9 4 170 79 52 10.4 0.96 30.9 Y N 
24 0.5 7.7 4 599 550 106 
   
N N 
25 0.5 6.2 3.8 69 21 61 
   
N N 
26 0.4 8 4.3 495 304 82 13.2 1.2 48.6 N N 
27 0.5 5.8 3.6 190 84 77 9.3 0.86 39.2 Y N 
28 0.1 6.9 3 132 54 59 
   
Y N 
29 0.2 7.4 4 40 41 90 
   
N N 
30 0.2 6.6 3.6 82 33 41 
   
N N 
31 0.2 6.6 3.8 100 38 70 
   
N N 
32 0.5 6.1 3.3 434 189 130 10.9 1 48.4 Y N 
33 3.5 4.8 1.8 1112 704 335 12.5 1.15 37.9 Y N 
34 1.2 7 3.8 264 113 101 
   
Y N 
35 2.2 4.8 3 6860 2958 91 24.3 2.16 45.8 Y N 
36 0.6 5.2 2.8 583 342 57 10.8 0.99 40.3 Y N 
37 0.2 5.8 4.1 257 84 66 
   
N N 
38 0.1 6.7 3.7 128 63 39 9.6 0.88 45.4 Y N 
39 0.2 7.3 4.1 76 73 75 10 0.92 34.2 Y N 
40 7.8 4.2 2.1 1284 400 246 32.3 2.83 53.6 Y N 
41 0.2 7.6 4.1 101 134 96 9.4 0.86 40.1 Y N 
42 0.1 6.1 3.5 363 182 68 10.3 0.95 62.9 Y N 
43 0.5 5 2.7 744 337 66 10.1 0.93 40.2 N N 
44 0.1 6 3.2 44 27 62 
   
Y N 
45 0.4 6.1 2.9 315 190 83 9.6 0.89 38.9 N N 
46 0.2 7.1 4 102 63 54 
   
Y N 
47 0.4 6.6 2.9 2800 920 85 18.9 1.74 170 Y N 
48 0.2 6.6 3.5 70 18 44 11.4 1.07 31.6 Y N 
49 0.2 6.5 3.8 71 60 63 12.4 1.16 33.3 N N 
50 0.6 5.9 2.5 111 74 189 
   
Y N 
51 0.2 5.4 2.8 349 114 161 10.7 0.99 58.1 Y Y 
52 0.2 5.3 3.4 173 85 50 13.1 1.23 39.3 N N 
53 1 6.1 2.9 235 144 184 
   
Y Y 
54 0.2 6.7 3.3 78 23 204 
   
Y N 
55 0.3 4.9 2.3 327 186 101 12.7 1.19 26.8 Y N 
56 0.3 5 2.5 693 230 63 14.9 1.39 42.5 Y N 
57 0.2 6.6 4.3 40 25 126 
   
N N 
58 0.8 6.6 3.8 197 101 63 
   
Y N 
59 0.2 6.4 3.6 294 113 78 
   
N N 
60 0.3 6.8 3.7 40 30 66 11.3 0.07 35.6 Y N 
61 0.5 6 3.5 259 199 64 
   
Y N 
62 0.5 7 3.5 284 25 76 9.8 0.91 34.3 N N 
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 Proteinuria CSBlood Culturegrowth NS1Ag DenIgM DenIgG Malaria 
 
1 Y N 
 
Y Y Y N 
2 Y N 
 
N Y Y N 
3 Y N 
 
Y Y Y N 
4 N N 
 
Y Y Y N 
5 Y Y ESBL ENTEROBACTER Y Y Y N 
6 Y N 
 
Y Y Y N 
7 
 
N 
 
Y Y N N 
8 Y N 
 
N Y Y N 
9 N N 
 
N Y Y N 
10 N N 
 
Y Y Y N 
11 N N 
 
Y Y Y N 
12 Y N 
 
Y Y Y N 
13 N Y NFGNB N Y N N 
14 Y N 
 
Y N Y N 
15 Y N 
 
Y N Y N 
16 N N 
 
N Y Y N 
17 Y N 
 
N Y Y N 
18 Y N 
 
Y N N N 
19 Y N 
 
Y Y Y N 
20 Y N 
 
Y N Y N 
21 Y N 
 
N Y Y N 
22 N N 
 
Y Y Y N 
23 Y N 
 
Y Y Y N 
24 N N 
 
Y Y Y N 
25 Y N 
 
Y N N N 
26 N N 
 
Y N N N 
27 Y N 
 
Y Y Y N 
28 Y N 
 
Y N Y N 
29 N N 
 
N Y Y N 
30 N N 
 
Y Y Y N 
31 N N 
 
Y N N N 
32 Y N 
 
Y Y Y N 
33 Y N 
 
Y Y Y N 
34 Y N 
 
Y N N N 
35 Y N 
 
Y Y Y N 
36 Y N 
 
N Y Y N 
37 N N 
 
Y N Y N 
38 Y N 
 
Y Y Y N 
39 Y N 
 
N Y Y N 
40 Y N 
 
N Y Y N 
41 Y N 
 
Y Y Y N 
42 Y N 
 
Y Y Y N 
43 N N 
 
Y Y Y N 
44 Y N 
 
Y N N N 
45 N N 
 
N Y Y N 
46 Y N 
 
N Y Y N 
47 Y N 
 
Y Y Y N 
48 Y N 
 
Y Y Y N 
49 N N 
 
Y Y Y N 
50 Y N 
 
N Y N N 
51 Y Y CONS Y Y Y N 
52 N N 
 
Y Y Y N 
53 Y N 
 
N Y Y N 
54 Y N 
 
Y Y N N 
55 Y N 
 
Y Y Y N 
56 Y N 
 
Y Y Y N 
57 N N 
 
Y Y N N 
58 Y N 
 
N Y Y N 
59 N N 
 
Y Y Y N 
60 Y N 
 
Y N N N 
61 Y N 
 
Y Y Y N 
62 Y N 
 
N Y Y N 
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 VWFCBA ECG CXR USGABd DenSeverity StayDuration SOFAHighest PltLowest 
 
1 147.5 1 1 2 3 6 4 17000 
2 304 4 1 
 
2 3 3 20000 
3 259.5 1 1 
 
2 6 3 39000 
4 309 1 3 2 2 5 4 15000 
5 134.5 1 1 2 2 4 3 42000 
6 180.5 4 1 
 
2 4 4 13000 
7 172 4 1 
 
2 0 2 51000 
8 227.5 4 1 
 
1 0 2 57000 
9 240.2 4 1 
 
1 0 2 78000 
10 121.8 4 1 
 
2 0 4 17000 
11 190 4 5 
 
2 12 4 12000 
12 117.5 4 1 
 
3 5 5 11000 
13 175.5 1 2 
 
1 3 2 58000 
14 76.7 1 1 
 
3 5 4 12000 
15 135 1 1 1 2 6 4 12000 
16 108 4 1 
 
2 4 4 10000 
17 90.5 1 1 
 
2 4 5 21000 
18 71.9 1 3 2 3 8 5 11000 
19 100.7 1 1 
 
2 5 4 7000 
20 128 1 5 1 1 6 3 30000 
21 182.5 1 1 
 
2 4 4 8000 
22 94.5 1 1 
 
2 5 4 16000 
23 132.5 1 1 
 
2 12 4 77000 
24 143 1 1 1 2 0 3 30000 
25 60.6 1 1 2 3 5 4 20000 
26 60.2 4 1 
 
2 4 4 14000 
27 61.1 1 1 1 2 4 4 12000 
28 139 1 5 2 2 7 4 7000 
29 112.1 4 1 
 
1 0 2 53000 
30 121 1 1 
 
1 4 4 19000 
31 148 4 1 
 
1 0 3 31000 
32 79.3 1 1 
 
2 6 5 12000 
33 256 1 1 
 
2 10 7 16000 
34 95.7 1 3 2 2 5 6 6000 
35 97.7 1 3 2 3 10 8 14000 
36 109.5 4 3 2 2 4 4 14000 
37 74.2 4 1 
 
2 5 4 9000 
38 91.8 1 1 
 
2 4 4 11000 
39 117 1 1 
 
2 4 4 19000 
40 297.5 2 2 2 3 6 21 15000 
41 101.1 1 1 
 
2 4 5 11000 
42 39.7 1 3 
 
2 3 4 6000 
43 86.3 1 1 
 
1 6 2 58000 
44 171.5 1 1 
 
1 3 2 71000 
45 159.5 4 1 
 
2 5 4 19000 
46 287 1 1 
 
1 5 2 58000 
47 180.5 3 2 
 
3 3 7 17000 
48 251 1 5 1 1 4 2 53000 
49 205.5 1 1 2 2 6 4 19000 
50 136 1 1 
 
2 9 5 4000 
51 152.5 4 1 
 
3 30 7 19000 
52 101 1 1 
 
1 5 4 6000 
53 207 1 1 
 
2 4 6 6000 
54 246.5 4 5 
 
2 6 4 19000 
55 99.7 1 2 2 3 10 5 47000 
56 175 1 3 
 
3 4 5 13000 
57 38.3 4 1 
 
1 5 3 38000 
58 105 1 1 
 
2 4 5 16000 
59 157 4 1 
 
1 0 3 41000 
60 295 1 1 
 
2 6 3 20000 
61 159 4 1 
 
2 3 4 15000 
62 161 1 1 
 
1 3 3 25000 
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 SGPTHighest Outcome IcuCare RRT Transfusion VentSupport AKI VasoReq PltTX 
 
1 508 1 N N N N Y N 0 
2 430 1 N N N N N N 0 
3 60 1 N N N N N N 0 
4 47 1 N N N N N N 0 
5 271 1 N N Y N N N 4 
6 149 1 N N N N N N 0 
7 605 1 N N N N N N 0 
8 43 1 N N N N N N 0 
9 106 1 N N N N N N 0 
10 52 1 N N N N N N 0 
11 97 1 Y N Y N N N 6 
12 31 1 N N Y N N N 4 
13 34 1 N N N N N N 0 
14 1125 1 N N N N N N 0 
15 363 1 N N N N N N 0 
16 81 1 N N N N N N 0 
17 219 1 N N N N Y N 0 
18 428 1 N N N N N N 0 
19 38 1 N N N N N N 0 
20 74 1 N N N N N N 0 
21 127 1 N N N N N N 0 
22 523 1 N N N N N N 0 
23 79 1 N N N N Y N 0 
24 550 1 N N N N N N 0 
25 21 1 N N N N N N 0 
26 304 1 N N N N N N 0 
27 84 1 N N Y N N N 4 
28 96 1 N N Y N N N 4 
29 41 1 N N N N N N 0 
30 130 1 N N N N N N 0 
31 38 1 N N N N N N 0 
32 189 1 N N Y N Y N 2 
33 704 1 N N N N N N 0 
34 143 1 N N Y N Y N 2 
35 2958 1 N N N N Y N 0 
36 342 1 N N N N N N 0 
37 84 1 N N N N N N 0 
38 63 1 N N N N N N 0 
39 151 1 N N N N Y N 0 
40 400 2 Y Y Y Y Y Y 12 
41 134 1 N N N N Y N 0 
42 200 1 N N Y N N N 2 
43 337 1 N N N N N N 0 
44 27 1 N N N N N N 0 
45 190 1 N N N N N N 0 
46 63 1 N N N N N N 0 
47 920 2 Y N Y Y Y Y 2 
48 18 1 N N N N N N 0 
49 85 1 N N N N N N 0 
50 100 1 N N Y N N N 2 
51 1487 1 Y N Y Y Y N 17 
52 180 1 N N Y N N N 4 
53 144 1 N N N N N N 0 
54 23 1 N N Y N N N 2 
55 186 1 N N Y N N N 0 
56 230 1 N N N N N N 0 
57 118 1 N N N N N N 0 
58 101 1 N N Y N N N 4 
59 113 1 N N N N N N 0 
60 167 1 N N N N N N 0 
61 159 1 N N Y N N N 1 
62 262 1 N N N N N N 0 
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 FFPTX CryoTx PregComplex GestAge Gravida 
 
1 0 0 
   2 0 0 
   3 0 0 
   4 0 0 
   5 4 0 
   6 0 0 
   7 0 0 
   8 0 0 
   9 0 0 
   10 0 0 
   11 5 0 
   12 0 0 
   13 0 0 
   14 0 0 
   15 0 0 
   16 0 0 
   17 0 0 
   18 0 0 
   19 0 0 
   20 0 0 N 32 3 
21 0 0 
   22 0 0 
   23 0 0 
   24 0 0 
   25 0 0 
   26 0 0 
   27 2 0 
   28 0 0 N 16 1 
29 0 0 
   30 0 0 
   31 0 0 
   32 0 0 
   33 0 0 
   34 8 0 
   35 0 0 
   36 0 0 
   37 0 0 
   38 0 0 
   39 0 0 
   40 11 33 
   41 0 0 
   42 2 0 
   43 0 0 N 18 1 
44 0 0 
   45 0 0 
   46 0 0 
   47 4 0 
   48 0 0 N 8 2 
49 0 0 
   50 0 0 
   51 20 57 Y 38 1 
52 8 0 
   53 0 0 
   54 2 0 N 34 1 
55 0 0 
   56 0 0 
   57 0 0 
   58 0 0 
   59 0 0 
   60 0 0 
   61 0 0 
   62 0 0 
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